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a 
 
Abstract 
 
Ciprofloxacin is a fluoroquinolone, broad spectrum antibacterial agent 
where it fights against both Gram positive and Gram negative bacteria. It usually 
enters the bacteria via porins such as OmpF in E. coli and binds with the DNA 
proteins called DNA gyrase or DNA topoisomerase IV and a bacterial DNA to 
form a ternary complex in the cytoplasm. Mutation in the regulatory gene of 
bacterial DNA affects the biological synthesis of porins where it reduces the 
porins, and this usually associates with overproduction of efflux pumps, which 
lead to low concentration of ciprofloxacin in the bacteria. Therefore, it does not 
reach to the fatal level and the bacteria are still able to survive even though they 
are exposed to antibiotics. This condition is called antibiotic resistance. ‘Trojan 
Horse’ strategy is one of the strategies to solve this phenomenon, where the 
antibiotic is smuggled into the cytoplasm of the bacteria by a vector called 
siderophore, which in nature, it is secreted by the bacteria to solubilise the ferric 
iron and enter the bacteria through the active pump for their survival. Our 
research group has synthesised many new siderophore-drug conjugates that 
based on the fluoroquinolone as the drug and δ-hydroxycarboxylate-type of 
siderophore as a vector. In this project, different polarities of 1,5-citrate 
ciprofloxacin conjugates were successfully synthesised and screened with a 
panel of clinically relevant bacteria and found that the using 1,5-citrate as a 
siderophore and hydrophilicity of siderophore-drug conjugates can improve 
marginally the efficacy of the drug conjugates. 
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spectrum 
13C NMR  Carbon-13 Nuclear Magnetic 
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COSY      Correlation spectroscopy 
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MRSA  Methicillin-resistant Staphylococcus 
aureus 
m/z      mass is to charge ratio 
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Omp      outer membrane protein 
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PTR      phase transfer reaction 
QRDR  quinolone-resistance determining 
region 
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rt      room temperature 
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1 Introduction 
 
1.1 Antibiotics 
 
An antibiotic is a chemical agent used to delay or to stop the growth of 
bacteria and ultimately, kill the bacteria. An example of a naturally occurring 
antibiotic is the β-lactam antibiotic, Penicillin 1, which is produced by fungal 
Penicillium strains[1]. Extracting natural antibiotics from microorganisms gives 
only a limited quantity of potential dugs; therefore, scientists have designed 
and synthesised semi-synthetic and synthetic antibiotics which have a wide 
range of bacterial cell targets. Examples of semi-synthetic antibiotics are 
tigecycline 2[2] and clarithromycin 3[3]. An example of a synthetic antimicrobial 
agent is ciprofloxacin 4, a member of the class of synthetic antimicrobials 
known as fluoroquinolones[4, 5]. (Figure 1) 
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Figure 1: Structures of Penicillin 1, tigecyclin 2, clarithromycin 3 and ciprofloxacin 4 
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1.2 Antibiotic Resistance 
 
Antibiotic resistance is the phenomenon where the bacteria develop 
mechanisms to enable them to survive even though they are exposed to 
antibiotics[5]. The overuse or misuse of antibiotics leads to mutations in the 
bacteria; they can develop these mutations during antibiotic therapy or after 
treatment. There are three common mechanisms of resistance (Figure 2); (1) 
production of enzymes that hydrolyse or chemically modify the antibacterial 
agent, (2) alteration of the target enzymes and (3) reduction of intracellular 
concentration of the antibiotic by either reduction of porins in the outer 
membrane of bacteria or up regulation of efflux pumps. 
 
(3) Reduce 
Permeability
(1) Antibiotic
Inactivation
(2) Drug-binding 
site  Alteration
= Antibiotic
Key:
Bacterial cell
 
 
Figure 2: A schematic diagram showing resistance mechanisms 
 
Escherichia coli shows examples of these resistance mechanisms. 
Frequent exposure to β-lactam antibiotics such as penicillin 1 and 
 3 
 
cephalosporins[6] lead to the β-lactamase gene in E. coli over expressing 
lactamase[7]. In some cases, the overproduction is due to the mutation in an 
up-promoter gene[8] or changes in transcriptional regulation[9]. β-Lactamase is 
the enzyme produced by Gram negative and Gram positive bacteria in order 
to bind[10, 11] or hydrolyse[11] β-lactam antibiotics which ultimately prevent them 
from killing the bacteria. Since β-lactamase contains an active site that is 
structure specific for the β-lactam ring[12], an irreversible inhibitor has been 
designed to combat the action of this enzyme. One treatment regime is the 
combination of amoxicillin 5 (the antibacterial agent) and clavulanic acid 6 (the 
β-lactamase inhibitor) (Figure 3). Unfortunately, the idea of combining the 
drug and the inhibitor still has some limitations, some strains of E. coli can 
produce β-lactamases that are not only capable of hydrolysing the antibiotic, 
but they also synthesise plasmid-encoded β-lactamase TEM-1 which is 
capable of combating the inhibitor[6]. 
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Figure 3: Structure of amoxicillin 5 and clavulanic acid 6 
 
A key resistance mechanism displayed by many bacteria is alteration of 
the antibiotic binding sites of the intracellular target[13]. This type of antibiotic 
resistance is due to the numerous single amino acids substitutions which 
reduce the binding affinity of the antibiotic to a target enzyme[13]. For example, 
rifampicin 7 (Figure 4) is an antibiotic that interacts with the β-sub unit of 
bacterial RNA polymerase[14]. Changing of the structure of the active site for 
rifampicin 7 in RNA polymerase was due to amino acid substitutions, or small 
deletions and insertions within highly conserved regions of the RNA 
polymerase β-sub unit, resulting in antibiotic resistance[15]. 
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Figure 4: Structure of rifampicin 7 
 
Before an antibacterial agent can interact with an intracellular target 
protein or enzyme, it must pass through the bacterial cell membrane. Porins 
and passive diffusion through the cell membrane allow antibacterial agents to 
enter the bacterial cell. In some mutant Gram negative bacteria, the 
permeation of hydrophilic molecules through porins is reduced[16] due to 
mutations in regulatory genes[17]. For example resistance to fluoroquinolone 
antibiotics can be due to a decreased number of OmpF porins. 
 
A number of strategies have been developed in order to combat 
resistance mechanisms especially those that lower the intracellular drug 
concentration.  
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1.3 Development of Fluoroquinolone Antibiotics 
 
Nalidixic acid 9 was found during the synthesis of chloroquine 8, an 
antimalarial agent[18]. Nalidixic acid 9 had a modest bacteriostatic activity 
towards Gram negative bacteria. It was only used for the treatment of kidney 
infections[5] and some enteric infections caused by members of the 
Enterobacteriaceae[5]. Structurally nalidixic acid 9 contains naphthyridone 
nucleus (two rings containing nitrogen atoms at position 1 and 8) [19] (Figure 
5).   
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Figure 5: Modification of chloroquinolone 8 to nalidixic acid 9 
 
Soon after its introduction, pathogenic organisms showed resistance 
towards nalidixic acid 9[19]. Therefore, chemical modifications were explored in 
order to increase its potency and spectrum to bypass resistance.  
 
Any chemical modification needs to retain the pharmacophore unit and 
structure, such as the carboxylic acid and the quinolone nucleus. 
 
The first modification gave rosoxacin 10[19] (see Figure 6). Rosoxacin 10 
showed the improvement in terms of activity over nalidixic acid 9[19].  
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Figure 6: 4-Quinolone pharmacophores 
 
Flumequine 11 (patented in 1973) was the first fluoroquinolone that 
substituted the hydrogen atom at position 6 with a fluorine atom which showed 
increased activity towards Gram positive bacteria because of greater DNA-
gyrase inhibition activity and increase in cell penetration[19]. 
 
Two decades after the introduction of nalidixic acid 9[19], norfloxacin 12 
(patented in 1978) was synthesised. It contained the combination of a fluorine 
atom at position 6 and a piperazinyl ring at position 7. The addition of the 
piperazinyl ring at position 7 increased the spectrum of its activity as it could 
kill most Gram negative bacteria and had greater efficacy on Gram positive 
bacteria by improving the penetration of the drug through the bacteria cell 
wall[19-21]. Unfortunately, norfloxacin 12 showed poor bioavailability[5]. 
Therefore, it was not used in systemic infections[19].   
 
Ciprofloxacin 4 (patented in 1981) has the addition of cyclopropyl ring at 
nitrogen-1 position which broadened the spectrum and enhanced the activity. 
It can be used in systemic infections[19].  
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There are newer developments in fluoroquinolone antibiotics. For 
example, sparfloxacin and levofloxacin have good activity against Gram 
positive bacteria in respiratory infections[17]. Other newer fluoroquinolones are 
trovafloxacin and clinafloxacin which are used against anaerobic bacteria[17]. 
 
Fluoroquinolone antibiotics are classified into four generations. (Table 1) 
 
Generation 4- Quinolones Activity strength 
First 
Nalidixic acid 
Cinoxacin 
Moderate Gram negative 
Second 
Lemofloxacin 
Norfloxacin 
Enoxacin 
Broad spectrum to Gram 
negative and atypical 
bacteria, but limited to Gram 
positive 
Ofloxacin 
Ciprofloxacin 
Third 
Levofloxacin 
Sparfloxacin 
Gatifloxacin 
Moxifloxacin 
Broad to Gram negative and 
atypical bacteria. Also 
improve Gram positive 
Fourth 
Trovafloxacin 
Clinafloxacin 
Broad Gram negative, 
improve Gram positive and 
kill some of anaerobic 
pathogens 
 
Table 1: Generations of 4-quinolone 
 
1.3.1 Mode of Action 
1.3.1.1 Cell Penetration 
 
Before inhibiting the target intracellular enzymes, fluoroquinolone must 
firstly penetrate through the bacterial cell wall and the inner cell membrane. In 
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Gram negative bacteria, there are three different ways for fluoroquinolones to 
enter the bacteria[5]. They are hydrophilic pathways involving porins, 
hydrophobic pathways involving lipid bilayers and self-promoted pathways for 
cationic molecules[5].  
 
Cell uptake via porins is based on hydrophobicity and molecular 
weight[5]. In order to enter a bacterial cell through these proteins, molecules 
must have a hydrophilic characteristic[22] and molecular weight of 600 Daltons 
and less[16]. Even though porins accept molecules with low molecular weight, 
they do not accept hydrophobic molecules. It has been reported by Caulcott et 
al. that ciprofloxacin shows enhanced uptake via OmpF when compared to 
Ofloxacin, this is proposed to be due to its three dimensional shape and 
hydrophilicity[5, 23] (Table 2). 
 
Polarity 4-Quinolone 
Molecular weight  
(Da) 
Hydrophilicity 
(Log P < 0.1) 
Ciprofloxacin 331.4 
Norfloxacin 319.3 
Enoxacin 320.3 
Intermediate 
polarity 
(Log P 0.1-2.0) 
 
Miloxacin 263.2 
Ofloxacin 360.4 
Pefloxacin 333.4 
Hydrophobicity 
(Log P > 2.0) 
Nalidixic acid 232.2 
Oxolinic acid 261.2 
Difloxacin 399.4 
 
Table 2: Hydrophobicity and molecular weight (Da) of fluoroquinolones  
 
1.3.1.2 Intracellular target 
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 After passing into the bacterial cytoplasm, fluoroquinolones inhibit 
cell division by interrupting the key DNA supercoiling enzymes, gyrase and 
topoisomerase IV. 
 
Ciprofloxacin 4 inhibits DNA synthesis by targeting cytoplasmic gyrase 
(topoisomerase II) in Gram negative bacteria[24, 25], or cytoplasmic 
topoisomerase IV in Gram positive bacteria[24]. 
 
In Gram negative bacteria, cytoplasmic gyrase is responsible for 
changing relaxed DNA into super-coiled DNA[17]. The gyrase protein is a 
tetramer containing A and B subunits. The A is responsible for DNA cleavage 
and re-sealing, and the B subunit responsible for the transfer of energy from 
ATP hydrolysis[17]. Ciprofloxacin 4 disturbs gyrase during the re-sealing of 
double-stranded DNA by forming a quinolone-topoisomerase II-DNA ternary 
complex at its binding site in GyrA[17, 24]. The formation of this ternary complex 
prevents the release of DNA which eventually leads to cell death[20]. 
 
In Gram positive bacteria, the role of DNA topoisomerase IV is similar to 
cytoplasmic gyrase and is the primary target for ciprofloxacin[24] in these 
strains. Fluoroquinolone also forms a ternary complex with DNA[26] and 
topoisomerase IV during bacterial cell division, this then prevents the DNA 
replication, ultimately, causing cell apoptosis[20].  
 
Linus L Shen et al.[27] hypothesised that in order for the cell to 
apoptosise successfully, four molecules of ciprofloxacin 4 are required, and 
stack in the binding pocket[27] (Figure 7). Intermolecular interactions such as 
hydrogen bonding and hydrophobic interactions are essential for stabilising 
the complex between drug, bacterial DNA and enzymes[27]. Therefore, the 
functional groups in ciprofloxacin 4 play a role in stabilisation (Figure 8). 
 
 10 
 
N
N
N
H
F
O
OH
O
N
N
H
N O
F
OH
O
N
N
N
H
F
O
O
OH
N
N
H
N
F
O
O
OH
 
 
Figure 7: Proposed stacking of ciprofloxacin 4
[27] 
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Figure 8: Proposed important domains for stabilising the drug-DNA-enzyme 
complex
[27]
 
 
1.3.2 Resistance Mechanisms Displayed By Fluoroquinolone 
Antibiotics 
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The primary resistance mechanism is the mutation of the target 
enzymes, DNA gyrase in Gram negative bacteria and DNA topoisomerase IV 
in Gram positive bacteria. Alteration is due to substitutions of amino acids[28] 
within the quinolone-resistance determining region (QRDR) in the A subunit of 
gyrase or in the parC subunit in topoisomerase IV. In E. coli, QRDR is a 
narrow region between amino acid residues of 51 to 106 in DNA gyrase[29]. 
The amino acid substitutions result in the fluoroquinolone no longer forming a 
complex with gyrase-bacterial DNA so bacterial cell division occurs even in 
the presence of intracellular fluoroquinolones.  
 
The secondary resistance mechanism to fluoroquinolone is a decrease 
in cell membrane permeability[30]. This is due to mutations in the regulatory 
genes[17] which lead to a reduction in the expression of the outer membrane 
porins such as OmpFa in E. coli [31] and D2a in P. aeruginosa[32]. Decreased 
expression of cell membrane porins leads to a sub lethal intracellular 
concentration of fluoroquinolones. 
 
Another factor that lowers the intracellular concentration of 
fluoroquinolones is overproduction of efflux proteins. Efflux proteins are 
proteins that expel the drug from the cell. For example E. coli  has the AcrAB-
TolC efflux system[33] that pumps out toxic chemicals including 
fluoroquinolones. Overproduction of AcrA proteins will expel ciprofloxacin from 
the bacterial cell[20] reducing the intracellular ciprofloxacin concentration 
allowing it to survive exposure to ciprofloxacin 4. 
 
Another more recently discovered mode of resistance is gyrase-
protecting proteins. These proteins are designed to temporarily protect gyrase 
enzymes[34] from attack by fluoroquinolones. For example, Qnr proteins 
protect DNA gyrase from interaction with ciprofloxacin 4[35] resulting in failure 
to form the DNA-gyrase-ciprofloxacin.  
 
                                                          
a
 OmpF and D2 are responsible porins for the uptake of hydrophilic fluoroquinolones. 
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1.4 Siderophores 
 
Iron is the fourth most abundant element in the Earth’s crust[36, 37]. It is 
one of the most important transition metals in biological proteins and is found 
in key enzymes such as haemoglobin. Under aerobic conditions, iron is 
present as ferric iron, which has a very low solubility in water at neutral pH 
(Ksp of Fe (OH)3 approx. 10
-39 M)[36, 38, 39]. 
 
Due to the limited availability of soluble iron in the environment, bacteria 
synthesise and secret low molecular weight, high affinity ferric iron-chelating 
agents called siderophores[37] in order to survive. The main function of 
siderophores is to capture, solubilise and transport the iron in the form of a 
Fe3+- siderophore complex[38]. 
 
All siderophores contain iron-binding sites[36]. In order for the 
siderophore to successfully bind iron it has an arrangement of atoms which 
can chelate ferric iron[36] forming an iron-siderophore complex. Since the 
bound ferric ion possesses a d5 high-spin electronic configuration[40] and the 
siderophore acts as a ligand, an octahedral complex is formed[41] which 
generally contains three bidentate chelation units per ferric iron[42] (Figure 9). 
Due to the chelate effect, the thermodynamic stability of these complex is 
increased[42].  
 
Fe
N
O
O
N
H
O
NH
R
N
NH
ON
O
CH3
OH
O
O
 
 13 
 
 
Figure 9: Iron (III) complex of a hydroxamate siderophore 
 
1.4.1 Siderophore Classes 
 
Siderophores can be divided into four different classes based on the 
nature of iron binding moieties: α-hydroxycarboxylate, catecholate/ phenolate, 
hydroxamate and mixed ligand siderophores. 
 
1.4.1.1 α-Hydroxycarboxylate Siderophores 
 
Siderophores that contain both hydroxyl and carboxylate ligands are 
classed as α-hydroxycarboxylate siderophores. The ligands are linked to a 
suitable backbone to form the siderophore. The simplest siderophore in this 
class is citric acid 14[38, 43] which is thought to carry the ferric iron as the bis 
ferric-citrato complex, (Fe-citrate)2 which is recognised by the outer 
membrane protein, FecA[38] in E. coli. A more structurally complex example of 
α-hydroxycarboxylate siderophore is achromobactin 13 which contains three 
α-hydroxycarboxylate groups: two α-hydroxycarboxylates from α-keto-
glutarate and one from citric acid 14[38].  Other siderophores in this class, 
Staphyloferrin A 15, secreted by Staphylococcus hyicus[44] and Rhizoferrin 16 
isolated from Rhizophus and members of Zygomycetes[45], both have two citric 
acids units linked by ornithine and diaminobutane backbones[38], respectively. 
Another example of this class of siderophore is vibrioferrin 17, a bis α- 
hydroxycarboxylate siderophore, where the α-hydroxycarboxylate ligands are 
derived from citric acid and α-ketoglutarate[38]. (Figure 10) 
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Figure 10: α-hydroxycarboxylate siderophores 
 
1.4.1.2 Catecholate/ Phenolate Siderophores 
 
Siderophores that utilise phenolate or 2, 3-dihydroxybenzoate (DHB) to 
chelate Fe3+ are classified as catecholate/ phenolate siderophores. The first 
tricatecholate siderophore isolated in 1970 was Enterobactin 18 which was 
isolated from culture fluids of Aerobacter aerogenes, E. coli and Salmonella 
typhimurium[46]. Enterobactin 18 is cyclic tris-(2,3-dihydroxybenzoyl-L-
serine)[38] where L-serine forms a cyclic triester scaffold which holds the three 
catecholate ligands. Bacillibactin 19, extracted from Bacillus subtilis[47] is 
another cyclic tris catecholate siderophore which is structurally similar to 
Enterobactin. In Bacilibactin, L-threonine is used as a cyclic triester scaffold 
with glycine spacers elongating the chelating arms[47]. Salmochelin  20, 
isolated from S. enteric and uropathogenic E. coli[38, 48] is a glucosylated 
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Enterobactin derivative, where the two catechols contain a glucose moiety[38, 
49]. (Figure 11) 
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Figure 11: Catecholate siderophores 
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1.4.1.3 Hydroxamate Siderophores 
 
Hydroxamate siderophores contain hydroxamate groups as their iron 
binding ligands. Microorganisms synthesise this type of siderophores by direct 
oxidation of amines followed by acylation[50, 51].  Examples of tris hydroxamate 
siderophores are Ferrioxamines, which are comprised of alternate units of 
succinic acid and a monohydroxylated diamine[38]. Desferrioxamine B (DFOB) 
21 is used clinically for treating iron overload [38, 52]. Other ferrioxamines are 
Desferrioxamine E 22 which is a cyclic siderophore and Desferrioxamine G 23 
which is linear[53]. (Figure 12) 
 
N
H
O
N
OH
NHO
O
N
OH
O
N
H
O
N
O
OH
22
NH
O
N
OH
OH O
N
OH
O
NH
O
N
O
OH
NH2
O
23
NH
O
N
OH
O
N
OH
O
NH
O
N
O
OH
NH2
21
 
Figure 12: Ferrioxamine siderophores 
 
1.4.1.4 Mixed Ligand Siderophores 
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Mixed ligand siderophores contain more than one type of ligand. An 
example is aerobactin 24 which contains α-hydroxycarboxylate and 
hydroxymate ligand moieties from citric acid and 6-[acetyl (hydroxy) amino]-2-
aminohexanoic acid, respectively. Petrobactin 25[54], isolated from Bacillus 
species, is another example of a mixed ligand siderophore. This siderophore 
combines a α-hydroxycarboxylate with two 3,4-dihydroxybenzoyl ligand 
moieties. Ornibactin 26[55] isolated from strains of Pseudomonas is composed 
of linear hydroxamate and hydroxycarboxylate ligands. (Figure 13) 
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Figure 13: Mixed ligand siderophores 
 
1.4.2 Fe (III)-Siderophore Complex Transport Mechanism 
 
The ferric iron may be released from the siderophore complex by 
reduction to ferrous iron at the extracellular surface of the bacteria and the 
iron is taken up[40]. Alternatively, the whole siderophore complex is internalised 
by the bacteria and the iron released inside the cell[40].  
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Gram negative bacteria contain an outer membrane, periplasmic space 
and a cytoplasmic membrane; whereas in Gram positive bacteria have one 
thick peptidoglycan cell wall and cytoplasmic membrane. In Gram negative 
bacteria, the transportation of the ferric iron-siderophore complex is more 
complex than in Gram positive bacteria.  
 
In bacteria, especially Gram negative bacteria, an energy dependent 
system is required in order for the whole complex[56] to pass from the 
extracellular space to the intracellular cytoplasmic space. Firstly, the 
complexes need to be recognised by the outer membrane binding protein 
which carries the complex into the periplasm. The complex is taken by the 
cytoplasmic membrane transport proteins to the cytoplasm of the bacteria[38]. 
In Gram positive bacteria, the Fe3+- siderophore complexes are recognised by 
specific membrane receptor proteins and directly transported into the 
cytoplasm by ABC-transport proteins[38, 57]. 
 
1.4.2.1 Outer Membrane Recognisation 
 
The outer membrane of Gram negative bacteria contains receptors used 
to recognise Fe(III)-siderophore complexes. This outer membrane receptor-Fe 
(III) ion-siderophore interaction is highly specific [58]. The specificity depends 
on the ligands used to form the iron siderophore complex. There are many 
receptors that have been discovered through the crystallisation method, X-ray 
and genetic analyses[38]. FhuA is used to transport the hydroxamate type of 
siderophore[59], FepA, the catecholate-type of siderophore[60] and FecA 
receptor for δ-hydroxycarboxylate-type of siderophores[61] in E. coli.  
 
All of these membrane proteins have similar core structures and 
domains. All of them consist of a 22 antiparallel β-strand barrel and a ‘cork’[62]. 
The difference between these protein receptors is the protein-iron-siderophore 
complex binding site where it is ‘unique’ to the particular metal-siderophore 
complexes[38].  
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The outer membrane receptor interacts with tonB-ExbB-ExbD complex 
that is anchored in the inner membrane[38, 63]. This complex is responsible for 
the transduction of the proton motive force energy to the receptor protein so 
that the Fe3+-siderophore complex can enter the periplasmic space[38, 63].  
 
1.4.2.2 Periplasmic-Binding Protein 
 
Once it has entered the periplasmic space, the complex is bound and 
delivered into the cytoplasmic membrane by periplasmic binding proteins such 
as FhuD (hydroxamate siderophores)[64], FepB (enterobactin)[65], and FecB 
(ferric dicitrate)[66].  
 
1.4.2.3 Cytoplasmic ABC Transporters 
 
After binding to the periplasmic-binding protein, the ferric iron-
siderophore complex is then translocated across the cytoplasmic membrane 
by an ABC transporter (ATP Binding Cassette)[38]. This protein consists of two 
subunits: one which is used to span the membrane and the second is able to 
hydrolyse ATP to supply energy for translocation[37]. Hydrolysis or/and binding 
of ATP causes  a change the conformation of the protein so that the whole 
complex can enter the cytoplasmic space of the bacteria[67].  
 
1.4.2.4 Iron Release 
 
Once it has entered the cytoplasm, iron is released by mechanisms 
involving either degradation or chemical modification of the iron carrier and/or 
reduction of the iron(III) to iron(II)[68, 69]. For example, pyoverdin in P. 
aeruginosa, iron is released not through the mechanism of chemical 
modification, but it is released from the chelator by reduction of iron[69, 70].  
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1.5 ‘Trojan Horse’ System 
 
Hydrophilic molecules such as ciprofloxacin 4 usually enter the bacteria 
via porins, such as OmpF. The resistance mechanism that reduces the 
expression of these porins can lead to a sub-lethal concentration of antibiotic. 
In order to circumvent this problem, a ‘Trojan horse’ strategy has been 
devised, where a drug can be delivered by the ferric-siderophore transport 
system. This strategy is inspired by natural siderophore-drug conjugates[40]. 
Examples of natural siderophore-drug conjugates are Albomycin 27[71], 
Ferrimycin 28[72] and Salmycin D 29[73] (Figure 14). 
 
1.5.1 Natural Siderophore-Drug Conjugates 
 
The ‘Trojan Horse’ strategy is inspired by the natural siderophore-drug 
conjugates. Albomycins 27[71], use δ-N-hydroxy-δ-N-acetyl-L-ornithine 
residues to chelate ferric iron, with the antibiotic attached via serine spacer[36, 
74]. Another example of natural siderophore-drug conjugates is Ferrimycins 
28[72] which uses ferrioxamine B as the siderophore, conjugated to a toxin via 
an amide linker. Salmycins D 29[73] utilise a trihydroxamate siderophore 
conjugated to an aminoglycoside antibiotic through a dicarboxylic acid 
spacer[74]. These three natural siderophore-drug conjugates are not being 
used clinically since they are not readily available and their antibiotic modes of 
action are complex[36]. It has also been shown that organisms rapidly develop 
resistance to these natural siderophore-drug conjugates[36, 75]. (Figure 14) 
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Figure 14: Natural siderophore-drug conjugates 
 
1.5.2 Synthetic Siderophore-Drug Conjugates 
 
The components of a synthetic ‘Trojan Horse’ strategy consist of a 
siderophore, a linker and a drug (Figure 15). The siderophore must retain the 
ability to bind iron to enable it to be taken up into the bacterial cell. The linker 
is used to chemically conjugate the drug to the siderophore. This linker will 
either remain attached the drug to the complex or released chemically or 
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enzymatically within the bacterial cell[76]. The choices of the drug are 
depending on the bacterial target and its suitability towards chemical 
conjugation[51].  
 
Linker/ SpacerSiderophoreFe3+ Drug
 
Figure 15: Components in the ‘Trojan Horse’ System 
 
1.5.2.1 Cyanuric Acid-β-Lactam Conjugates 
 
Manuka Ghosh and Marvin J. Miller have successfully synthesised 
cyanuric acid-based siderophore-β-lactam conjugates 30 (Figure 16) and 
evaluated their biological activities[77]. Carbacephalosphorin and its derivative-
Lorabid, were used as the antibiotics and isocyanuric-based trihydroxamate 
as the siderophore component. They also have shown that these type of 
synthetic siderophore-drug conjugates were active against E. coli X580 in 
preliminary biological test[77].  
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Figure 16: Cyanuric-β-Lactam conjugate 
 
1.5.2.2 Mixed-Ligand Siderophore-β-Lactam Conjugates 
 
Arun Ghosh et al.[78] have successfully synthesised synthetic 
siderophore-drug conjugates which consist of two bis catecholate and one 
hydroxamate ligands conjugated to β-lactam antibiotics, carbacephem and 
Lorabid to form mixed ligand-carbacephem 31 and mixed ligand-Lorabid 32[78] 
(Figure 17). They also evaluated the biological activity of the synthetic 
conjugates and found that using mixed ligand siderophores gave active 
compounds. They proposed success in using mixed ligand siderophores was 
due to the presence of multiple siderophore transport pathways in the outer 
cell membrane of the bacteria[78]. 
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Figure 17: Synthetic mixed ligand-drug conjugates 
 
1.5.2.3 Citrate Based-β-Lactam Conjugates 
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Arun Ghosh and Marvin J. Miller[79] have reported citrate based-β-lactam 
conjugates using citric acid as the siderophore and carbacephem and Lorabid 
as the antibacterial agents to form citrate-carbacephem conjugate 33 and 
citrate-Lorabid conjugate 34[79] (Figure 18). They also evaluated the efficacy of 
these conjugates against E. coli X580, and illustrated that both of the 
conjugates suppressed bacterial growth in iron-sufficient media, and 
completely inhibited the growth of the bacteria in iron-deficient conditions[79]. It 
was concluded that a simple α-hydroxycarboxylate siderophore was accepted 
by the bacteria and delivered via the active-delivery system[79].  
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Figure 18: Synthetic citrate-based siderophore-drug conjugates 
 
1.5.2.4 Citrate Based-Ciprofloxacin Conjugates 
 
Recently, Md Saleh et al.[80] successfully synthesised citrate based-
ciprofloxacin conjugates, 1,3-citric acid-ciprofloxacin 35 and 1,5-citric acid-
ciprofloxacin 36 (Figure 19). They also evaluated the drug conjugates efficacy 
against clinically relevant bacteria. It was proposed that both citrate based-
ciprofloxacin conjugates were able to reach to the intracellular target, but 
there was no improvement on the activity of the drug conjugates when 
compared to the parent antibiotic, ciprofloxacin 4[80]. 
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Figure 19: Synthetic citrate-ciprofloxacin conjugates 
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1.6 Objectives 
 
The aim of this project is to synthesise new siderophore-drug conjugates 
with ciprofloxacin as the drug and a citric acid as the siderophore unit. 
Different amino acids will be used as linkers to provide a spacer between the 
siderophore and the drug. A citrate-ciprofloxacin conjugate with a glycine 
linker 37 has been synthesised previously and it showed antimicrobial activity 
albeit lower than the parent antibiotic. The citrate-ciprofloxacin conjugate 38 
with glycine linker but with different regiochemistry at the citric acid moiety will 
be synthesised to allow a direct comparison with 37.  An alternative linker, L-
serine will also be explored as this linker has hydrogen bonding potential, 
increasing the hydrophilicity of the siderophore-drug conjugate 39. The 
conjugates will be screened in the Bradford Infection Group, University of 
Bradford. 
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Figure 20: Structures of citric acid-ciprofloxacin conjugates 
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2 Results and Discussions 
 
2.1 1, 5-Citrate-ciprofloxacin conjugate using Glycine as 
the linker 
 
Citric acid 14 is one of the simplest siderophores[37]. It is a δ-
hydroxycarboxylate-type siderophore containing two potential iron-binding 
groups, hydroxyl and carboxylic acid. E. coli[81] and P. aeruginosa[82] use citric 
acid 14 to solubilise, capture and transport Fe3+ from the environment via the 
active pumps such as FecA, even though citric acid itself has low affinity for 
Fe (III)[83]. The successful use of citric acid by bacteria, means that it has 
potential to be used as a shuttle for transporting an antibiotic across the 
bacterial membrane via the siderophore transport mechanism in the Trojan 
Horse strategy. The 1,3-citrate-glycine-ciprofloxacin conjugate 37 has been 
synthesised[84], and screened against a panel of clinically relevant bacteria. 
Synthesis of the regioisomeric conjugate 38 would allow investigation into the 
influence of the citrate residue on the antimicrobial activity of the conjugate. 
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The proposed synthesis of the first target molecule; 1,5-citrate-Gly-
ciprofloxacin conjugate 38 is shown in Scheme 1. 
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Scheme 1: The proposed synthesis of 38 
 
The first step toward the target molecule requires selective protection of 
the primary carboxylic acid groups. This was achieved by carefully controlled 
methylation[85] (Scheme 2). 
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Scheme 2: Regioselective methyl protection of citric acid 
 
1,5-dimethyl citrate 40 was successfully synthesised from commercially 
available citric acid 14 using sulfuric acid in anhydrous methanol. The reaction 
gave 23 % yield of 1,5-dimethyl citrate 40. Reaction time is critical when 
synthesising 40 as prolonged reaction time gives an increased amount of 1,3, 
5-trimethyl citrate 41. Any 41 formed in the reaction was separated from 1,5-
dimethyl citrate 40 by extraction into chloroform, the minimum amount of 
1,3,5-trimethyl citrate 41 formed in the reaction was limited to 11 %. 
 
The successful synthesis of 40 was supported by 1H NMR spectroscopy. 
Inspection of the spectrum showed a signal at 3.66 ppm with a relative 
integration of six, corresponding to two methyl groups at position 1 and 5. In 
the mass spectrum, m/z peak at 221.0658 [M+H]+ was observed 
corresponding to the molecular formula of C8H13O7. 
 
Two other peaks were observed in the mass spectrum at m/z 189 and 
171. The m/z peak 189 is proposed to arise from the parent ion m/z 221 
through cyclisation. Further fragmentation results in m/z peak 171 (Scheme 
3). 
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Scheme 3: Proposed cyclisation and fragmentation of 1,5-dimethyl citric acid 40 in 
mass spectrometry, respectively 
  
Ciprofloxacin methanoate 42 was synthesised from free ciprofloxacin 4 
using thionyl chloride-mediated methylation (Scheme 4). 
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Scheme 4: Synthesis of ciprofloxacin methanoate 42 from ciprofloxacin 4 
 
Commercially available ciprofloxacin 4 was esterified using anhydrous 
methanol under reflux in the presence of thionyl chloride. Ciprofloxacin 
methanoate 42 was isolated in 76 % crude yield. 
 
The successful synthesis of 42 was supported by 1H NMR spectroscopy, 
the spectrum showed a signal at 3.90 ppm with a relative integration of three 
due to the methyl group. The presence of the methyl group was also 
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supported by analysis of the carbon-13 spectra, where an extra peak at 51.7 
ppm was observed. 
 
The successful synthesis of ciprofloxacin methyl ester 42 was confirmed 
by mass spectrometry where the m/z peak at 346.1563 [M+H]+ was observed 
corresponding to molecular weight of C18H21FN3O3. 
 
Ciprofloxacin methanoate 42 was then conjugated with the amino acid 
linker, N-(tert-butoxycarbonyl)-Gly-OH 43 using EDC-mediated coupling 
reaction[86]. Nakajima et. al[87] states  that the coupling reaction is best done 
under basic conditions, and therefore, a non-nucleophilic Hünig base, 
diisopropylethylamine (DIPEA) was used in the reaction (Scheme 5). 
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Scheme 5: Amide coupling reaction of 44 
 
The linker-drug conjugate 44 was initially synthesised using anhydrous 
DMF as a solvent, but it gave only 55 % crude yield contaminated by DMF 
impurities. Therefore, in order to avoid using DMF, different solvents such as 
anhydrous methanol and methanol-aqueous media were explored. Using 
methanol as a solvent is, in theory, problematic due to its ability to act as a 
nucleophile and the amide coupling reaction being a nucleophilic acyl 
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substitution reaction. Therefore, a polar-aprotic solvent was expected to be 
the best for this reaction. Using anhydrous methanol increased the reaction 
yield by 14 %. Methanol-aqueous media was also tried at higher temperature 
and was observed to double the yield compared to the reaction with 
anhydrous DMF (Table 3). 
 
Reaction Solvent 
Percentage yield 
of isolated 44 
Temperature 
O C 
1 dry DMF 55 25  
2 dry MeOH 69 25 
3 MeOH-aqueous media 84 40  
 
Table 3: Isolated yield of 44 using different solvents systems 
 
The idea of using this polar-protic solvent with EDC.HCl as an activator 
was proposed by Yangwei et al.[88]. 
 
The successful conjugation of ciprofloxacin methanoate 42 and N-(tert-
butyoxycarbonyl)-Gly-OH 43 to form conjugate 44 was supported by 1H NMR 
spectroscopy where the equivalent methyl protons of the N-(tert-
butoxycarbonyl) protecting group were found at 1.47 ppm in the spectrum. 
The singlet corresponding to the secondary piperazinyl amine proton of 
ciprofloxacin methanoate 42 at 2.17 ppm was absent, replaced by a triplet 
signal at 5.51 ppm. The triplet peak was due to the enantiotropic protons of 
the glycine group. This was confirmed by COSY where the amide proton at 
5.51 ppm coupled with the enantiotropic protons at 4.04 ppm (Appendix 5). 
Therefore, this shows the presence of glycine in the linker-drug conjugate 44. 
Mass spectrometry showed a m/z peak at 503.2320 [M+H]+ was observed 
corresponding to molecular weight of C25H32FN4O6.  
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After successfully synthesising both 1,5-dimethyl citrate 40 and N-(tert-
butoxycarbonyl)-Gly-ciprofloxacin methanoate 44, they were then coupled to 
form methyl protected siderophore-drug conjugate 46 (Scheme 6). 
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Scheme 6: Multistep syntheses towards the synthesis of 45 
 
Before coupling 1,5-dimethyl citrate 40 to the drug conjugate 44, the N-
(tert-butoxycarbonyl) protecting group of glycine was deprotected by acid 
hydrolysis using 4M HCl in anhydrous methanol[89] to form an ammonium salt. 
The salt was not isolated, but coupled to 1, 5-dimethyl citrate 40 using 
EDC.HCl and HOBt.H2O under basic conditions. 
 
Synthesis of 45 was initially carried out using anhydrous DMF, which 
gave only 33 % yield of 45, contaminated by DMF impurity. Different solvents 
were explored. Anhydrous acetonitrile was used since its boiling point is lowb 
and, it can, therefore, easily be removed from the reaction. Unfortunately, it 
dissolved the ammonium salt slowly and only gave 21 % isolated yield of 45 
(Table 4).  
 
                                                          
b
 Boiling point of acetonitrile is 81.6 °C 
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Methanol-aqueous media was also explored as this solvent system 
improved the previous reaction but no significant improvement was observed 
here since it only gave 35 % overall yield of 45 (Table 4). 
 
Therefore, it can be concluded that changing the solvent system does 
not improve the yield of 45 within experimental error. 
 
Reaction Solvent 
Percentage of yield 
of 45 
Temperature 
OC 
1 DMF 33 25 
2 Acetonitrile 21 25 
3 MeOH: aqueous media 35 25 
 
Table 4: Yields of 45 with different solvent system 
 
Another strategy was to maintain anhydrous DMF as the reaction 
solvent, as this dissolves the organic salt, but the temperature was increased 
to 40 OC. Work up of the reaction gave 40 % yield of 45. 
 
The successful synthesis of 45 in all reaction was supported in ESI-MS 
and 1H NMR spectroscopy. This was supported by the 1H NMR spectrum 
which showed the single peak for tert-butyl of N-(tert-butoxycarbonyl) 
protecting group at 1.45 ppm was missing, and a new peak had appeared at 
3.55 ppm with a relative integration of six protons corresponding to the methyl 
esters of 1,5-dimethyl citrate apparent. From the mass spectrometry, the m/z 
peak at 605.2257 [M+H]+ was observed corresponding to the molecular 
formula of C28H34FN4O10. 
 
The methyl protected siderophore-drug conjugate 45 was then 
deprotected using base-mediated hydrolysis to give siderophore-drug 
conjugate 38 (Scheme 7). 
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Scheme 7: Synthesis of siderophore-drug conjugate 38 
 
The new siderophore-drug conjugate 38 was synthesised by the global 
deprotection of methyl esters by base hydrolysis with 0.1M of 
tetrabutylammonium hydroxide (TBAH) in methanol, this gave 38 in 40 % 
isolated yield.  
 
This successful synthesis of 38 was firstly inspected from 1H NMR 
spectrum, where peaks at 3.55 ppm and 3.73 ppm for methyl esters in 1,5-
citric acid and ciprofloxacin respectively were absent (Spectrum 1). Successful 
cleavage of the methyl ester protecting groups was also supported by 13C 
NMR spectroscopy, where the carbon-13 peaks at 51.5 ppm and 55.1 ppm 
were absent (Spectrum not shown). 
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Spectrum 1: Proton NMR spectrum of 38 
 
The successful synthesis of 38 was further investigated by mass 
spectrometry using ESI (+) and ESI (-). The protonated molecular ion was 
fragmented using collision induced dissociation (CID). From the CID 
experiment, six peaks were investigated: 563 [M+H]+, 545, 527, 509, 389  and 
371 (Scheme 8). 
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Scheme 8: Possible fragmented molecules from CID mass spectra 
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2.2 1,5-Citrate-ciprofloxacin conjugate using L-serine as 
the linker 
 
The 1,3-citrate-ciprofloxacin conjugate 46 with a hydrophobic linker was 
previously synthesised by our research group[84]. Its antimicrobial activity was 
determined on a panel of clinically relevant bacterial strains. From the 
biological investigation, the siderophore-drug conjugate 37 was consistently 
more active than 46. It is suggested that the lower activity of 46 is probably 
due to the lower hydrophilicity. A new siderophore-drug conjugate 39 with 
increase hydrophilicity, when compared to 37 and 46 was designed and 
synthesised. L-serine was chosen as the linker, due to the presence of CH2-
OH, which can potentially increase the hydrogen bonding. 
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The proposed synthesis of the second target molecule 39 is shown in 
Scheme 9.  
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Scheme 9: The proposed synthesis of 39 
 
In order to successfully synthesise siderophore-drug conjugate 39, 
ciprofloxacin methanoate 42 was firstly conjugated with N-(tert-
butoxycarbonyl)-L-Ser-OH 47 by EDC-mediated coupling reaction (Scheme 
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10). N-(tert-butoxycarbonyl)-L-Ser-OH 47 was chosen, as Yangwei et al. 
reports that no protection is required for sensitive functional groups such as 
the hydroxyl group[88] using an EDC-mediated coupling. In our hands, the 
hydroxyl group of L-serine was reactive, giving 49 as a by-product of the 
reaction.  
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Scheme 10: Conjugation of ciprofloxacin methanoate 42 and N-(tert-butoxycarbonyl)-
L-Ser-OH 47 gave two linker-drug conjugates 48 and 49 
 
This was confirmed by 1H NMR spectroscopy where the spectrum 
showed the resonances indicative of 49 (Spectrum 2). The formation of 49 
was also supported by mass spectrometry where a signal m/z 720.3250 was 
observed corresponding to the molecular formula of C34H47FN5O11. 
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Spectrum 2: Partial 
1
H NMR spectrum of the mixture of 48 and 49 
 
These two products were problematic to separate by chromatography so 
attention was turned to alternative coupling reagents. 
 
HBTU was tried and only one spot was detected by TLC analysis of the 
crude reaction mixture.  
 
When using HBTU as a coupling reagent, tetramethyl urea is formed in 
the reaction. After work up, tetramethyl urea was detected in 1H NMR analysis 
with a signal at 2.68 (NMR spectrum not shown). Alternative reaction work ups 
were explored in order to isolate pure 48. 
 
Julius T. Su et a.l[90] report that tetramethyl urea can be removed by 
trituration with hexane. The crude linker-drug conjugate 48 was triturated but 
tetramethyl urea was still present. 
 
Luttringhaus and Dirksen[91] report that tetramethyl urea is soluble in 
aromatic hydrocarbons[91]. Therefore, trituration with toluene was tried, 
tetramethyl urea was successfully removed as the singlet peak for tetramethyl 
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urea was absent in the proton NMR spectrum of 49. After modifying the work 
up, 48 was isolated in 72 % yield (Scheme 11). 
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Scheme 11: Synthesis of 48 using HBTU as amide-coupling reagent 
 
The successful synthesis of the linker-drug conjugate 48 was supported 
by 1H NMR spectroscopy where a singlet peak at 1.38 ppm with a relative 
integration of nine corresponding to the tert butyl of the N-(tert-
butoxycarbonyl) protecting group was observed. The presence of two doublet-
doublet peaks due to the protons at position 21 and a singlet, broad peak at 
4.44 ppm due to the proton from the hydroxyl group were also present. In 
addition, the peak for the amine in ciprofloxacin methanoate 42 at 2.17 ppm 
was absent and replaced by a doublet for the amide bond at 6.89 ppm. The 
splitting for this signal is due to the coupling of the amide proton with only one 
enantiotopic proton from L-serine (COSY at Appendix 8). The successful 
synthesis of 48 was further supported by mass spectrometry where an m/z 
peak at 533.2407 [M+H]+ was observed corresponding to the molecular 
formula of C26H34FN4O7. 
 
Before removal of the N-(tert-butoxycarbonyl) protecting group, the 
hydroxyl group of L-Serine was firstly protected with acetyl group (Scheme 
12).  
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Scheme 12: Acetylation reaction 
 
The linker-drug conjugate 50 was first isolated only by a simple aqueous 
washing. Unfortunately, this gave only 33 % crude yields of 50 contaminated 
by acetic acid. The low yield was due to the cleavage of the acetyl group 
during washing with 0.05M aqueous hydrochloric acid during work up.  
 
Therefore, in order to improve the yield as well as purify the compound 
50, the work up was optimised by washing with saturated sodium hydrogen 
carbonate and brine, this followed by purification with column chromatography 
gave 79 % isolated yield of 50.   
 
The successful synthesis of 50 was confirmed by inspection of the 
proton NMR spectrum where a signal at 1.99 ppm with a relative integration of 
three was observed, due to the methyl protons of the acetyl protecting group.  
The successful synthesis of 50 was also supported by mass spectrometry 
where a m/z peak at 575.2527 [M+H]+ was observed corresponding to the 
molecular formula of C28H36FN4O8. 
 
After successfully synthesising the linker-drug conjugate 50, it was then 
conjugated with 1,5-dimethyl citrate 40 using an EDC-mediated coupling 
reaction after removal of the N-(tert-butoxycarbonyl) protecting group 
(Scheme 13).  
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Scheme 13: Amide coupling reaction between the protected citric acid 40 and the 
drug conjugate 51 
 
Synthesis of the protected siderophore-drug conjugate 51 initially began 
with the deprotection of the N-(tert-butoxycarbonyl) protecting group by acid 
hydrolysis using 4M HCl in anhydrous MeOH[89]. The reaction was then 
followed by conjugation with 1,5-dimethyl citrate 40 using similar technique 
used in the successful synthesis of 45.  
 
Unfortunately, 51 was not observed in neither the 1H NMR spectrum nor 
the mass spectrum, it appeared that, not unsurprisingly, the acetyl protecting 
group was cleaved on treatment with 4M aqueous HCl. This unwanted 
deprotection was confirmed by proton NMR spectroscopy, where in the 
spectrum, the peak of methyl from the acetyl group at 1.99 ppm was absent. 
This was supported by mass spectrometry, a peak at m/z 433.1900 [M+H]+ 
was observed corresponding to the molecular weight of C21H26FN4O5, the m/z 
peak of ammonium salt 50ii (Scheme 15).   
 
The acid hydrolysis used for the deprotection of N-(tert-butoxycarbonyl) 
protecting group had hydrolysed the acetyl group. Hence, the strategy 
towards the synthesis of 39 was modified (Scheme 14). 
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Scheme 14: New strategy towards the synthesis of 39 
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 Instead of the acetyl protecting group being used to protect the hydroxyl 
group, 1,5-dimethyl citrate 40 was used. Therefore, two equivalents of 1, 5-
dimethyl citrate 40 were used during the coupling reaction after removal of the 
N-(tert-butoxycarbonyl) and acetyl protecting groups (Scheme 15). 
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Scheme 15: New strategy forming 52 
 
However, even though two equivalents of 1,5-dimethyl citrate 40 were 
added during the reaction, two spots were observed in the TLC analysis of the 
crude reaction mixture. Prolonged reaction time did not result in further 
reaction. One equivalent of EDC.HCl was added every three hours until only 
one spot was observed by TLC analysis. Purification by column 
chromatography afforded 56 % yield of 52. 
  
The successful synthesis of 52 was confirmed by the proton NMR 
spectrum where the singlet peak of N-(tert-butoxycarbonyl) protecting group at 
1.39 ppm was absent. The presence of two molecules of 1,5-dimethyl citrate 
40 in 52 was supported by the presence of signals at 2.74-3.01 ppm with a 
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relative integration of eight corresponding to eight protons from four 
diastereotopic protons of two 1,5-dimethyl citrate molecules in 52. 
 
From the mass spectrum, it showed a m/z peak at 837.2849 [M+H]+ 
corresponding to the molecular formula of C37H46FN4O17.  
 
Finally, the protected siderophore-drug conjugate 52 underwent the 
global methyl ester deprotection 39 (Scheme 16). 
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Scheme 16: Base hydrolysis of esters to form siderophore-drug conjugate 39 
 
The protected siderophore-drug conjugate 52 was reacted with 0.1M 
TBAH in methanol. This base hydrolysis gave 29 % yield of 39. 
  
Successful synthesis of 39 was confirmed by 1H NMR spectroscopy. 
The spectrum showed the methyl peak of ciprofloxacin and 1,5-citrate at 3.85 
ppm and 3.64-3.71 ppm, respectively, were absent (Spectrum 3).  
 
The removal of 1,5-citrate ester bond of L-serine was also confirmed by 
the proton NMR spectrum where the integration at 2.53-2.74 ppm was 
reduced from eight to four showing only two CH2 from only one 1, 5-citric acid 
moiety (Spectrum 3).  
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Spectrum 3: The spectrum of 39 at 400 MHz NMR at room temperature 
 
The cleavage of 1, 5-citric acid in hydroxyl ester was also confirmed by 
the presence of the hydrogen from the free hydroxyl group in the L-serine 
linker. In the 400MHz NMR spectrum, the broad, singlet peak for hydroxyl 
resonance overlapped the proton resonance at 4.78-4.95 ppm. The signals 
were resolved in the 700 MHz NMR spectrum (Spectrum 4). The presence of 
hydroxyl group in L-serine was proven by a D2O shake (B in Spectrum 6). 
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Spectrum 4: Partial spectra of 400 MHz and 700 MHz 
1
H NMR spectrum 
  
On close inspection of the 1H NMR spectrum of 39, the resonance for 
the amide proton appeared as a pseudo triplet at 8.18 ppm. COSY supported 
that this was indeed the amide proton as it was observed to couple with the 
proton at position 20 (Spectrum 5). 
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Spectrum 5: COSY spectrum shows coupling between the pseudo triplet amide 
resonance and proton at position 20 
 
This was then confirmed by deuterium exchange[92]. A D2O shake 
resulted in the disappearance of the pseudo triplet peak. In addition, during 
the deuteriation process, the resonance peak of the proton at position 20 
changed from a sextet to quartet, showing that this proton only coupled to the 
diastereotopic protons of R-CH2-OD (Spectrum 6).  
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Spectrum 6: Partial spectra of new siderophore-drug conjugate 39 with and without 
D2O 
 
The pseudo triplet signal could be due to racemisation during ester 
hydrolysis with a base. During hydrolysis, the pH was approximately 11 at 
room temperature. Daft and Coghill[93] suggest (without experimental 
evidence) that serine could be racemised at pH 9 at room temperature within 
one hour. However, Crawhall and Elliot[94] found that serine was readily 
racemised at pH 11.4, but at temperatures above 100 oC. Therefore, it was 
highly unlikely that a mixture of D and L-serine isomers were present in 39. 
 
The pseudo triplet resonance was further investigated using 700 MHz 
NMR spectroscopy. From the inspection of the spectrum, the pseudo triplet 
was resolved to form a doublet-doublet signal (Spectrum 7). From this it 
appears that the doublet-doublet was the amide proton from two different 
rotamers (Scheme 17). 
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Spectrum 7: Partially spectra of the second target molecule 39 at 400 MHz and 700 
MHz at ambient temperature 
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Scheme 17: Cis-trans isomerisation of amide bond 
 
This process was further investigated by variable temperatures 1H NMR 
spectroscopy. 
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From the analysis of 500 MHz NMR spectroscopy at variable 
temperatures, the chemical shift of the pseudo triplet was shifted to high field 
when the temperature was increased (Spectrum 11).  
 
The pseudo-triplet was also observed to broaden slowly once the 
temperature was increased, and at 363 K the pseudo triplet resonance 
appeared to come close forming a coalescence peak, unfortunately, the probe 
temperature could not be increased further. Therefore, the free activation 
energy could not be calculated. Once the temperature was reset to the 
ambient temperature, the broad pseudo triplet resonance returned to its 
original chemical shift (Spectrum 8).  
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Spectrum 8: Partial 
1
H NMR of 39 at variable temperatures at 500 MHz NMR 
spectroscopy 
 
As the temperature of the probe was increased, the aliphatic portion of 
39, which includes the 1,5-citric acid and L-serine signals became broad (A in 
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the Spectrum 9).  The aromatic signals of 39 (B of Spectrum 9) showed no 
difference at higher temperatures.  
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Spectrum 9: Partial 
1
H NMR spectra of the second target molecule 39 at 500 MHz at 
variable temperatures 
 
Thus, it can be concluded that the pseudo triplet of amide proton was 
due to the rotation barrier of cis and trans isomers around the amide bond. 
 
Successful synthesis of the new siderophore-drug conjugate 39 was 
supported by mass spectrometry. The spectrum showed an m/z peak at 
593.1912 [M+H]+ corresponded to the molecular formula of C26H30FN4O11. 
ESI-MS in negative mode was also used, and a m/z peak at 591.1763 [M-H]- 
was observed corresponding to the molecular formula of C26H28FN4O11. 
 
In CID, six signals were investigated: 593 [M+H]+, 575.2, 557.2, 539.2, 
503.2, 419.2 (Scheme18). The data obtained from CID was consistent with 
the proposed structure of 39. 
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Scheme 18: Possible fragmented molecule from CID spectrum 
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2.3 Biological Screening 
 
Two new siderophore-drug conjugates, 38 and 39 were successfully 
synthesised, and they were then screened against clinically relevant bacteria. 
The MIC (µg/ mL) reported was converted into nmol/ mL. Free ciprofloxacin 4 
was used as a reference.  
 
From table 5 it shows that conjugate 38 is more active than conjugate 
37 against a wide variety of bacterial strains. Changing the regioichemistry of 
the citrate has marginally improved the efficacy of 38 towards Gram positive 
bacteria and no significant improvement in activity was observed with Gram 
negative bacteria.  
 
Therefore, changing the regiochemistry of 1,3-citrate to 1,5-citrate 
siderophore improves the activity of the drug conjugates.  
 
From table 6 it shows that 39 was more active than 38 against few 
bacterial strains. Changing the polarity of the linker from glycine to L-serine 
does not improve the activity of the drug towards Gram positive bacteria, but 
only slightly improve towards Gram negative bacteria. 
 
Therefore, there is a marginal increase in the efficacy of the new 
siderophore-drug conjugates, 38 and 39 when the regiochemistry of the citrate 
was 1,5 and the lipophobicity was increased. These changes do not give 
activity comparable to free ciprofloxacin 4. 
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Table 5: The result for the investigation on pharmacophore of new siderophore-drug conjugates against clinically isolated bacteria 
                                                          
c
 Ciprofloxacin resistance 
d
 Methicillin-resistant staphylococcus aureus (MRSA) 
e
 Epidermic methicillin-resistant staphylococcus aureus (EMRSA) 
f
  Bacterial strain isolated from throat 
 
Bacterial strains 
Control 
 
Siderophore-drug conjugates 
 
Ciprofloxacin  38 37 Gram 
bacteria 
  MIC 
 
MIC 
Ratio 
MIC 
Ratio 
 µg/ mL nmol/ mL 
 
µg/ mL nmol/ mL µg/ mL nmol/ mL 
 Staphylococcus aureus (Oxford) NCTC 6571 0.25 0.755 
 
4 7.11 9.42 16 28.4 37.6 
 Staphylococcus aureus (HG-1) 
c
 
d
 
 
 
  
  
 Staphylococcus aureus-15 NCTC 13142 
e
 0.5 1.51 
 
4 7.11 4.71 16 28.4 18.8 
 Staphylococcus aureus-16 NCTC 13143  
c
 
e
  
 
 
  
+ Staphylococcus aureus BIG 0052 
c d 
0.5 1.51 
 
4 7.11 4.71 16 28.4 18.8 
 Staphylococcus epidermidis NCTC 11047 0.125 0.377 
 
2 3.56 9.44 16 28.4 75.3 
 Staphylococcus epidermidis NCTC 2749 0.25 0.755 
 
2 3.56 4.72 8 14.2 18.8 
 Staphylococcus haemolyticus NCTC 11042 0.125 0.377 
 
2 3.56 9.44 16 28.4 75.3 
 Escherichia coli NCTC 10418 0.06 0.181 
 
0.125 0.222 1.23 0.125 0.222 1.23 
 Escherichia coli BIG 0046 
c
 
 
 
  
 Coliform BIG 0051 
c
 
 
 
  
 Pseudomonas aeruginosa (Environmental) BIG 0039 0.25 0.755 
 
2 3.56 4.72 2 3.56 4.72 
 Pseudomonas aeruginosa (Clinical) BIG 0037 2 6.04 
 
16 28.4 4.7 16 28.4 4.70 
 Pseudomonas aeruginosa NCTC 10662 0.25 0.755 
 
4 7.11 9.42 2 3.56 4.72 
 Pseudomonas aeruginosa BIG 0063 0.25 0.755 
 
2 3.56 4.72 8 14.2 18.8 
 Serratia marcescens BIG 0011 = NCTC 1377 0.06 0.181 
 
1 1.78 9.83 0.5 0.889 4.91 
- Burkholderia cepacia BIG 0009 = NCTC 10744 0.5 1.51 
 
8 14.2 9.4 8 14.2 9.40 
 Burkholderia cepacia BIG 117  1 3.02 
 
8 14.2 4.7 8 14.2 4.70 
 Burkholderia cepacia BIG 118  0.25 0.755 
 
2 3.56 4.72 8 14.2 18.8 
 Burkholderia cepacia BIG 119  4 12.1 
 
  
 Burkholderia cepacia BIG 120  2 6.04 
 
16 28.4 4.7 
 
 Burkholderia cepacia BIG 121  8 24.1 
 
  
 Stenotrophomonas maltophilia N1127 
f
 2 6.04 
 
16 28.4 4.7 
 
 Stenotrophomonas maltophilia N1124 
f 
4 12.1 
 
  
 Stenotrophomonas maltophilia N1119 
f 
1 3.02 
 
16 28.4 9.4 
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key Not active 
Table 6: The result for the investigation of polarity of new siderophore- drug conjugates against clinically isolated bacteria 
 
Bacterial strains 
Control 
 
Siderophore-drug conjugates 
 
Ciprofloxacin  38 39 Gram 
bacteria 
  MIC 
 
MIC 
Ratio 
MIC 
Ratio 
 µg/ mL nmol/ mL 
 
µg/ mL nmol/ mL µg/ mL nmol/ mL 
 Staphylococcus aureus (Oxford) NCTC 6571 0.25 0.755 
 
4 7.11 9.42 2 3.38 4.48 
 Staphylococcus aureus (HG-1)
 c d 
 
 
  
  
 Staphylococcus aureus-15 NCTC 13142 
e 
0.5 1.51 
 
4 7.11 4.71 8 13.5 8.94 
 Staphylococcus aureus-16 NCTC 13143 
c
 
e  
 
 
  
+ Staphylococcus aureus BIG 0052 
c d 
0.5 1.51 
 
4 7.11 4.71 4 6.75 4.47 
 Staphylococcus epidermidis NCTC 11047 0.125 0.377 
 
2 3.56 9.44 2 3.38 8.97 
 Staphylococcus epidermidis NCTC 2749 0.25 0.755 
 
2 3.56 4.72 2 3.38 4.48 
 Staphylococcus haemolyticus NCTC 11042 0.125 0.377 
 
2 3.56 9.44 2 3.38 8.97 
 Escherichia coli NCTC 10418 0.06 0.181 
 
0.125 0.222 1.23 0.125 0.211 1.17 
 Escherichia coli BIG 0046 
c 
 
 
  
 Coliform BIG 0051 
c 
 
 
  
 Pseudomonas aeruginosa (Environmental) BIG 0039 0.25 0.755 
 
2 3.56 4.72 2 3.38 4.48 
 Pseudomonas aeruginosa (Clinical) BIG 0037 2 6.04 
 
16 28.4 4.7 16 27 4.47 
 Pseudomonas aeruginosa NCTC 10662 0.25 0.755 
 
4 7.11 9.42 2 3.38 4.48 
 Pseudomonas aeruginosa BIG 0063 0.25 0.755 
 
2 3.56 4.72 2 3.38 4.48 
 Serratia marcescens BIG 0011 = NCTC 1377 0.06 0.181 
 
1 1.78 9.83 0.5 0.844 4.66 
- Burkholderia cepacia BIG 0009 = NCTC 10744 0.5 1.51 
 
8 14.2 9.4 4 6.75 4.47 
 Burkholderia cepacia BIG 117  1 3.02 
 
8 14.2 4.7 8 13.5 4.47 
 Burkholderia cepacia BIG 118  0.25 0.755 
 
2 3.56 4.72 2 3.38 4.48 
 Burkholderia cepacia BIG 119  4 12.1 
 
  
 Burkholderia cepacia BIG 120  2 6.04 
 
16 28.4 4.7 16 27 4.47 
 Burkholderia cepacia BIG 121  8 24.1 
 
  
 Stenotrophomonas maltophilia N1127 
f 
2 6.04 
 
16 28.4 4.7 8 13,5 2.24 
 Stenotrophomonas maltophilia N1124 
f 
4 12.1 
 
 
16 27 2.23 
 Stenotrophomonas maltophilia N1119 
f 
1 3.02 
 
16 28.4 9.4 8 13.5 4.47 
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3  Conclusions and Future Work 
 
3.1 Conclusions 
 
The Trojan horse strategy is a tool to target pathogenic bacteria where 
an antibacterial agent is conjugated to an essential nutrient such as a 
siderophore then taken into the bacterial cell by the nutrient transport 
pathway. The idea was inspired by natural siderophore-drug conjugates such 
as albomycins 27[71].  
 
Two siderophore-fluoroquinolone conjugates were successfully 
synthesised in this research. The siderophore component, carboxylate and 
the fluoroquinolone component, ciprofloxacin were linked by amino acids of 
diffferent hydrophilicity. Conjugate 38 was synthesised using a 1,5-citrate unit 
and a glycine link to ciprofloxacin. Conjugate 39 used a 1,5-citrate unit and a 
serine link to ciprofloxacin. 
 
The two synthesised carboxylate-ciprofloxacin conjugates were 
screened against a panel of clinically relevant bacteria. From the screening 
data, the carboxylate ciprofloxacin conjugates were found to be less effective 
than the parent drug ciprofloxacin. Conjugate 39 was marginally more active 
than 38 against some bacterial strains. The differences in activity could not be 
considered significant and no structure activity relationship (SAR) information 
could be concluded from the limited number of compounds synthesised. 
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3.2 Future work 
 
In order to prove whether the lowering of antimicrobial activity of 38 and 
39 when compared to the parent antibiotic is due to the lack of active transport 
across the bacterial cell membrane, a wider selection of conjugates need to 
be synthesised. The carboxylate siderophores used in this research are weak 
iron binders so the use of the siderophore components that show stronger iron 
binding could be explored.  
 
If the lowering of antimicrobial activity is due to reduced affinity towards 
the cytoplasmic target, DNA gyrase, the introduction of a bio-linker that allows 
the release of the antimicrobial inside the cytoplasm could also be explored. 
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4 Experimental 
 
4.1 General 
 
Solvents were purchased from Sigma Aldrich and stored over 4 Å molecular 
sieves. 
Thin layer chromatography was carried out using commercially available 
Merck F254 aluminium backed silica plates and the mobile phase indicated. 
Compounds were visualized using UV light (254 nm) or with indicators such 
as iodine, p-anisaldehyde and potassium permanganate. 
Melting points were recorded using a Bibby Stuart melting point apparatus 
and are uncorrected. 
All non-aqueous reactions were carried out under nitrogen, using flame dried 
glassware. Petrol refers to the fraction of petroleum ether boiling in the range 
40-60OC. Brine refers to a saturated aqueous solution of NaCl. Water is 
deionised water. 
Flash column chromatography was carried out using Davisil Flash Silica, 35-
60 micron. 
Infra-red spectra were recorded on an ATI Mattson Genesis FT-IR 
spectrometer. All samples were dried under vacuum before analysis. 
Proton and carbon NMR spectra were recorded on a Jeol ECX-400 (400 MHz) 
and (100 MHz) or a Bruker V-700 (700 MHz), with chemical shifts quoted in 
parts per million relative to CHCl3 [δH 7.26 and δC 77.0], DMSO [δH 2.54 and 
δC 42.45], or CD3OD [δH 3.35 and δC 4.78]. Carbon NMR spectra were 
assigned using DEPT experiments. Coupling constant (J) are quoted in Hertz. 
Positive and negative electrospray (ESI) mass spectra were acquired on a 
Finnigan LCQ mass spectrometer or a Bruker MicroToF mass spectrometer. 
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4.2 2-Hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-
oxobutanoic acid (40) 
 
OHO
OO
OH
O O
CH3CH3
53
40
2
4
6
8
910
 
C8H12O7 
220.08 g/mol 
 
To a mixture of 2-hydroxypropane-1,2,3-tricarboxylic acid 14 (10.0 g, 
52.1 mmol, 1 eq.) in anhydrous methanol (70 mL) was added concentrated 
sulphuric acid (0.2 mL, 3.8 mmol, 0.12 eq.). The reaction mixture was heated 
under reflux for 1 hour, and then allowed to cool to room temperature. The 
reaction mixture was diluted with deionised water (40 mL) and neutralised with 
the addition of solid calcium hydroxide. Excess calcium hydroxide was 
removed by filtration, and the filtrate was reduced in vacuo giving white solid.  
The white solid was suspended in deionised water (20 mL), and 
sonicated for 15 mins. And undissolved solid was removed by filtration. The 
filtrate was acidified to pH 0 by addition of concentrated hydrochloric acid. A 
white precipitate formed which was isolated then dissolved in an aqueous 
solution of sodium hydrogen carbonate (25 mL, 0.08 g/mL). The aqueous 
solution was washed with chloroform (3 x 40 mL). The aqueous layer was 
acidified to pH 0 with concentrated hydrochloric acid (2 mL) and 40 
precipitated as a white solid (2.60 g, 11.8 mmol, 23 %).  
Rf= 0.4 (DCM: MeOH: Formic acid; 10:1:1); 
1H NMR (400 MHz, MeOH-d4) δ (ppm): 3.66 (s, 6H, CH3), 2.94 (d, 
2JH-H= 15.4 
Hz, 2H, CH2), 2.82 (d, 
2JH-H= 15.4 Hz, 2H, CH2);  
13C NMR (100 MHz, MeOH-d4) δ (ppm): 176.4 (s, C-2), 171.8 (s, C-5, C-9), 
74.2 (s, C-3), 52.2 (s, C-6, C-10), 44.0 (s, C-4, C-8); 
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IR (KBr, cm-1): 3428 (br, OH), 1742 (s, C=O), 1438 (m, CH2), 1401 (w, CH3), 
1368 (w, CH3), 1300 (s, C-O), 1214 (s, C-O), 1126 (s, C-O); 
m.p. (OC): 105.1-107.2 OC; 
 m/z (ESI): 221 ([M+H]+, 100 %); 
HRMS (ESI): Calc. for C8H13O7 221.0656 [M+H]
+, found 221.0658 (-1.0 ppm 
error). 
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4.3 1,2,3-Trimethyl 2-hydroxypropane-1,2,3-
tricarboxylate (41) 
 
O O
O
OO
O
OH
CH3 CH3
CH3
41
12
3
4
5
67
8
9
10
 
C9H14O7 
234.2 g/mol 
 
To a mixture of 2-hydroxypropane-1,2,3-tricarboxylic acid 14 (10.0 g, 
52.1 mmol, 1 eq.) in anhydrous methanol (70 mL) was added concentrated 
sulphuric acid (0.2 mL, 3.8 mmol, 0.12 eq.). The reaction mixture was heated 
under reflux for 1 hour and then allowed to cool to room temperature. The 
reaction was diluted with deionised water (40 mL) and neutralised with the 
addition of solid calcium hydroxide. Excess calcium hydroxide was removed 
by filtration, and the filtrate was reduced in vacuo forming a white solid.  
The solid was suspended in deionised water (20 mL) and sonicated for 
15 mins. And undissolved solid was removed by filtration. The filtrate was 
acidified to pH 0 by addition of concentrated hydrochloric acid forming a white 
precipitate. The precipitate was isolated, and dissolved in an aqueous solution 
of sodium hydrogen carbonate (25 mL, 0.08 g/mL). The aqueous solution was 
extracted with chloroform (3 x 40 mL). The organic extract was dried over 
anhydrous MgSO4 (s), filtered and concentrated in vacuo affording 41 as a 
white solid (1.33 g, 5.68 mmol, 11 %). 
Rf= 0.79 (DCM: MeOH: Formic acid, 10:1:1); 
1H NMR (400 MHz, CDCl3) δ (ppm): 4.12 (s, 1H, H-10, OH), 3.83 (s, 3H, H-9, 
CH3), 3.68 (s, 6H, H-1, H-7, CH3), 2.92 (dd, 
2JH-H= 15.6 Hz, 2H, H-3/ H-5, 
CH2), 2.81 (dd, 
2JH-H= 15.6 Hz, 2H, H-3/ H-5, CH2); 
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13C NMR (100 MHz, CDCl3) δ (ppm): 173.8 (s, 1C, C-8), 170.2 (s, 2C, C-2, C-
6), 73.2 (s, 1C, C-4), 53.2 (s, 1C, C-9), 52.0 (s, 2C, C-1, C-7), 43.0 (2C, C-3, 
C-5); 
IR (KBr, cm-1): 3476 (w, OH), 1756 (s, C=O), 1740 (s, C=O), 1437 (m, CH2), 
1405 (w, CH3), 1372 (w, CH3), 1343 (w, CH3), 1229 (m, C-O), 1204 (m, C-O), 
1127 (m, C-O), 1070 (m, C-O); 
m.p. (OC): 97.7-99.4 OC; 
m/z (ESI): 235 ([M+H]+, 100 %); 
HRMS (ESI): Calc. for C9H15O7 235.0812 [M+H]
+, found 235.0817 (-2.3 ppm 
error. 
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4.4 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-
1-yl)-1,4-dihydroquinoline-3-carboxylate (42) 
 
NN
NH
O
F
O
O
CH3
8
4
11
42
1 2
3
5
6
79
10 12
13
14
15
16
17
18
 
C18H20FN3O3 
345.37 g/mol 
 
Thionyl chloride (13.1 mL, 181 mmol, 20 eq.) was added dropwise to a 
stirred solution of 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylic acid 4 (3.0 g, 9.1 mmol, 1 eq.) in anhydrous 
methanol (100 mL) at 0-5 ᵒC. The reaction was heated under reflux for 24 
hours. The reaction mixture was cooled to room temperature and 
concentrated in vacuo to give a yellow oil. 
The residue was basified to pH 10 by addition of a 5 % w/v aqueous 
solution of potassium carbonate (100 mL). The aqueous solution was 
extracted with dichloromethane (5 x 50 mL). The organic layer was then 
washed with deionised water (2 x 40 mL), diluted with 5 % w/v aqueous 
solution of potassium carbonate (100 mL) and re-extracted with 
dichloromethane (5 x 50 mL). The organic layers were dried over anhydrous 
MgSO4(s) filtered and the solvent was removed in vacuo to give 42 (2.38 g, 
6.89 mmol, 76 %). 
Rf = 0.30 (CHCl3: MeOH; 3:1); 
1H NMR (400 MHz, CDCl3) δ (ppm): 8.53 (s, 1H, H-4, CH), 8.01 (d, 
3JH-F= 
13.2 Hz, 1H, H-8, CH), 7.25 (d, 4JH-F= 7.0 Hz, 1H, H-11, CH), 3.90 (s, 3H, 
CH3), 3.40-3.45 (m, 1H, cyclopropane, CH), 3.23-3.26 (m, 4H, piperazine, 
CH2), 3.09-3.12 (m, 4H, piperazine, CH2), 2.17 (s, 1H, NH), 1.29-1.34 (m, 2H, 
cyclopropane, CH2), 1.12-1.15 (m, 2H, cyclopropane, CH2);  
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13C NMR (100 MHz, CDCl3) δ (ppm): 173.3 (d, 
4JC-F= 3.1 Hz, C-6), 166.5 (s, 
C-17), 153.6 (d, 1JC-F= 247.8 Hz, C-9), 148.5 (s, C-4), 145.2 (d, 
2JC-F= 10.0 Hz, 
C-10), 138.2 (s, C-12), 122.9 (d, 3JC-F= 7.3 Hz, C-7), 113.0 (d, 
2JC-F= 23.8 Hz, 
C-8), 109.8 (s, C-5), 104.8 (d, 4JC-F= 2.3 Hz, C-11), 51.7 (s, C-18), 50.9 (s, C-
13/14/15/16), 50.8 (s, C-13/14/15/16), 45.7 (s, C-13/14/15/16), 34.2 (s, C-3), 
7.6 (s, C-1, C-2); 
IR (KBr, cm-1): 2949 (w, CH), 2913 (w, CH), 2827 (w, CH), 1719 (s, C=O), 
1617 (s, C=O), 1486 (m, CH2), 1474 (w, CH2), 1343 (w,CH3), 1311 (m, C-O), 
1258 (s, C-F), 1160 (w, C-O), 1086 (m, C-O); 
m.p. (OC): 227.2-227.5 OC; 
m/z (ESI): 346 ([M+H]+, 100 %); 
HRMS (ESI): Calc. for C18H21FN3O3 346.1561 [M+H]
+, found 346.1563 (-0.5 
ppm error) 
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4.5 Methyl 7-[4-(2{[(tert-butoxy) carbonyl] amino} 
acetyl) piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (44) 
 
N
O
F
N
N
O NH
O
OCH3
CH3
CH3
O
O
CH3
44
1 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
 
C25H31FN4O6 
502.54 g/mol 
 
To a stirred suspension of methyl 1-cyclopropyl-6-fluoro-4-oxo-7-
(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 42 (0.25 g, 0.724 mmol, 1 
eq.), N-(tert-butoxycarbonyl)-Gly-OH 43 (0.13 g, 0.724 mmol) and HOBt. H2O 
(0.10 g, 0.724 mmol) in anhydrous MeOH (20 mL) was added EDC.HCl (0.17 
g, 0.87 mmol) and DIPEA (130 µL, 0.01 mmol). The reaction mixture was 
stirred for 24 hours at room temperature. 
The solvent was removed in vacuo affording a white residue which was 
diluted with deionised water (60 mL), and extracted with DCM (3x 80 mL). The 
organic extract was washed with deionised water (2x 50 mL), 0.05M aqueous 
HCl (2x 50 mL), 0.05M aqueous NaHCO3 (2x 50 mL), brine (2x 50 mL) and 
deionised water (2x 50 mL). The organic extract was dried over anhydrous 
MgSO4 (s), then concentrated in vacuo to give 44 as a white solid (0.25 g, 0.50 
mmol, 69 %).  
Rf= 0.8 (CHCl3: MeOH, 3:1); 
1H NMR (400 MHz, CDCl3) δ (ppm): 8.54 (s, 1H, H-4, CH), 8.09 (d, 
3JH-F= 
13.2 Hz, 1H, H-8, CH), 7.26 (d, 4JH-F= 7.0 Hz, 1H, H-11, CH), 5.51 (t, 
3J21-20= 
4.4 Hz, 4.4 Hz, 1H, NH), 4.03 (d, 3J20-21= 4.4 Hz, 2H, H-20, CH2), 3.90 (s, 3H, 
CH3), 3.86-3.88 (m, 2H, piperazine, CH2), 3.62-3.66 (m, 2H, piperazine, 
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CH2), 3.40-3.45 (m, 1H, cyclopropane, CH), 3.22-3.25 (m, 4H, piperazine, 
CH2), 1.45 (s, 9H, H-24, H-25, H-26, CH3), 1.33-1.37 (m, 2H, cyclopropane, 
CH2), 1.14-1.17 (m, 2H, cyclopropane, CH2); 
13C NMR (100 MHz, CDCl3) δ (ppm): 173.3 (d, 
4JC-F= 2.3 Hz, C-6), 167.5 (s, 
C-22), 166.5 (s, C-17), 156.2 (s, C-19), 155.5 (d, 1JC-F= 248.5 Hz, C-9), 148.8 
(s, C-4), 144.1 (d, 2JC-F= 10.8 Hz, C-10), 138.1 (s, C-12), 123.7 (d, 
3JC-F= 7.1 
Hz, C-7), 113.5 (d, 2JC-F= 23.8 Hz, C-8), 110.10 (s, C-5), 105.4 (d, 
3JC-F= 2.3 
Hz, C-11), 79.8 (s, C-23),  51.8 (s, C-18), 49.8 (s, C-13/14/15/16), 49.4 (s, C-
13/14/15/16), 44.1 (s, C-20), 41.9 (s, C-13/14/15/16), 41.5 (s, C-13/14/15/16), 
34.3 (s, C-3), 28.0 (s, C-24, C-25, C-26), 7.7 (s, C-1, C-2); 
IR (KBr, cm-1): 3297 (m, NH), 3068 (w, CH), 2974 (w, CH), 2844 (w, CH), 
1715 (s, C=O), 1699 (s, C=O), 1654 (s, C=O), 1617 (s, C=O), 1544 (m, NH), 
1491 (m, CH2), 1474 (m, CH2), 1454 (m, CH2), 1433 (m, CH2), 1352 (w, CH3), 
1323 (w, CH3), 1237 (s, C-F), 1164 (m, C-O), 1082 (m, C-O), 1029 (m, C-O); 
m.p. (OC): 193.4-193.5 OC; 
m/z (ESI): 503 ([M+H]+, 100 %); 
HRMS (ESI): Calc. for C25H32FN4O6 503.2300 [M+H]
+, found 503.2299 (0.2 
ppm error). 
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4.6 Methyl 7-[4-(2{[(tert-butoxy) carbonyl] amino} 
acetyl) piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (44) – modified synthesis 
 
N
O
F
N
N
O NH
O
OCH3
CH3
CH3
O
O
CH3
44
1 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
 
C25H31FN4O6 
502.54 g/mol 
 
To a stirred suspension of methyl 1-cyclopropyl-6-fluoro-4-oxo-7-
(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 42 (0.25 g, 0.724 mmol, 1 
eq.), N-(tert-butoxycarbonyl)-Gly-OH 43 (0.13 g, 0.724 mmol, 1 eq.) and 
HOBt.H2O (0.10 g, 0.724 mmol) in MeOH (3:2, 50 mL) were added - EDC.HCl 
(0.17 g, 0.87 mmol) and DIPEA (130 µL, 0.75 mmol). The reaction was stirred 
at 40OC for 3 hours. Deionised water (30 mL) was added and the reaction was 
stirred at room temperature for an hour. 
The solvent was removed in vacuo to give a white solid residue which 
was dissolved in deionised water (60 mL) and extracted with DCM (3x 80 mL). 
The organic extract was washed with deionised water (2x 50 mL), 0.05M 
aqueous HCl (2x 50 mL), 0.05M aqueous NaHCO3 (2x 50 mL), brine (2x 50 
mL) and deionised water (2x 50 mL). The organic extract was dried over 
anhydrous MgSO4(s) and concentrated in vacuo to give 44 as a white solid 
(0.31 g, 0.61 mmol, 84 %). 
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4.7 1,5-Dimethyl-3-[(2-{4-(1-cyclopropyl-6-fluoro-3-
(methoxycarbonyl)-4-oxo-1,4-dihydroquinoline-7-yl] 
piperazin-1-yl}-2-oxoethyl) carbamoyl]-3-
hydroxypentanedioate (45) 
 
N
O
F
N
N
NH
O
O
OH
O
O
CH3
OO
CH3
O
O
CH3
45
1 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
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24
25
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30
 
C28H33FN4O10 
604.58 g/mol 
 
To methanolic HCl (4M, 20 mL) at 0-5 OC, methyl 7-[4-(2{[(tert-
butoxy)carbonyl]amino}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1, 
4-dihydroquinoline-3-carboxylate 44 (0.20 g, 0.40 mmol, 1 eq.) was added. 
The reaction mixture was left to stir at room temperature for 16 hours. The 
reaction mixture was concentrated in vacuo and diluted with dry MeOH (~40 
mL). The solution was basified using triethylamine (~0.5mL, pH~8-9) and 
stirring was continued for 1.5 hours. The solvent was removed in vacuo 
affording a cream solid. 
The solid residue and 2-hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-
oxobutanoic acid 40 (0.09 g, 0.40 mmol) were dissolved in dry DMF (20 mL). 
To this suspension, DIPEA (350 µL, 1.99 mmol), and HOBt.H2O (0.06 g, 0.48 
mmol) were added followed by EDC.HCl (0.09 g, 0.48 mmol). The reaction 
mixture was heated at 40 OC for 24 hours and cooled to room temperature. 
The solvent was removed in vacuo affording a brown oily residue. 
The residue was dissolved in chloroform (60 mL) washed with saturated 
sodium hydrogen carbonate (5x 60 mL) and brine (5x 60 mL). The organic 
extract was dried over anhydrous MgSO4 (s), and concentrated in vacuo. The 
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residue was triturated with diethyl ether to affording 45 as a cream solid (0.096 
g, 0.16 mmol, 40 %). 
Rf= 0.9 (CHCl3: MeOH, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.45 (s, 1H, H-4, CH), 7.80 (t, 
3JH-H= 
4.4 Hz, 1H, NH), 7.78 (d, 3JH-F= 13.2 Hz, 1H, H-8, CH), 7.47 (d, 
4JH-F= 7.5 Hz, 
1H, H-11, CH), 4.04 (d, 3J20-21= 4.4 Hz, 2H, H-20, CH2), 3.93 (s, 3H, H-18, 
CH3), 3.69-3.72 (m, 2H, piperazine, CH2), 3.63-3.65 (m, 3H, piperazine, CH2, 
cyclopropane, CH), 3.55 (s, 6H, H-26, H-30, CH3), 3.22-3.32 (m, 4H, 
piperazine, CH2), 2.85 (d, 
2JH-H= 15.0 Hz, 2H, H-24/ H-28, CH2), 2.69 (d, 
2JH-
H= 15.0 Hz, 2H, H-24/ H-28, CH2), 1.23- 1.28 (m, 2H, cyclopropane, CH2), 
1.08-1.12 (m, 2H, cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 173.7 (s, C-22), 172.5 (d, 
4JC-F= 2.3 
Hz, C-6), 170.6 (s, C-25, C-29), 167.4 (s, C-17), 166.8 (s, C-19), 153.3 (d, 1JC-
F= 247.0 Hz, C-9), 149.1 (s, C-4), 144.3 (d, 
2JC-F= 10.8 Hz, C-10), 138.7 (s, C-
12), 122.7 (d, J= 7.1 Hz, C-7), 112.2 (d, 2JC-F= 21.5 Hz, C-8), 109.5 (s, C-12), 
107.1 (d, 3JC-F= 3.1 Hz, C-11), 73.9 (s, C-23), 55.1 (s, C-18), 51.5 (s, C-30, C-
26), 50.2 (s, C-13/ 14/ 15/ 16), 49.4 ( s, C-13/ 14/ 15/ 16), 43.1 (s, C-20),41.3 
(s, C-13/ 14/ 15/ 16),  40.9 (s, C-13/ 14/ 15/ 16), 38.4 (s, C-24, C-28), 34.9 (s, 
C-3), 7.5 (s, C-1, C-2); 
IR (KBr, cm-1): 3407 (br, OH), 2998 (w, CH), 2949 (w, CH), 2847 (w, CH), 
1719 (s, C=O), 1617 (s, C=O), 1486 (m, CH2), 1474 (m, CH2), 1437 (m, CH2), 
1380 (w, CH3), 1348 (m, CH3), 1311 (w, CH3), 1241 (s, C-F), 1209 (m, C-O), 
1164 (m, C-O), 1102 (m, C-O), 1082 (m, C-O), 1021 (s, OH); 
m.p. (OC): 153.9-155.3 OC; 
m/z (ESI): 605 ([M+H]+,100 %); 
HRMS (ESI): Calc. for C28H34FN4O10 605.2253 [M+H]
+, found 605.2257 (-0.7 
ppm error). 
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4.8  3-({2-[4-(3-Carboxy-1-cyclopropyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-7-yl) piperazin-1-yl]-2-oxoethyl} 
carbamoyl)-3-hydroxypentanedioic acid (38) 
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C25H27FN4O10 
562.5 g/mol 
 
To a stirred solution of TBAH in MeOH (1M, 0.5 mL) and deionised 
water (4.5 mL), was added  1,5-dimethyl-3-[(2-{4-(1-cyclopropyl-6-fluoro-3-
(methoxycarbonyl)-4-oxo-1,4-dihydroquinoline-7-yl]piperazin-1-yl}-2-
oxoethyl)carbamoyl]-3-hydroxypentanedioate 45 (0.08 g, 0.132 mmol, 1 eq.). 
The reaction mixture was stirred at room temperature for 18 hours. The 
reaction was quenched with 0.2M pyruvic acid in deionised water (0.2M, 2.0 
mL). The precipitate formed was isolated by filtration and washed with 
chloroform (2x 25 mL) to afford giving 38 (0.03 g, 0.053 mmol, 40 %). 
Rf= 0.32 (CHCl3: MeOH, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H, H-4, CH), 8.09 (t, 
3J21-20= 
5.3 Hz, 3J21-20= 5.3 Hz, 1H, H-21, NH), 7.95 (d, 
3JH-F= 13.2 Hz, 1H, H-8, CH), 
7.60 (d, 4JH-F= 7.6 Hz, 1H, H-11, CH), 4.03 (d, 
3J20-21= 5.3 Hz, 2H, H-20, CH2), 
3.80-3.86 (m, 1H, cyclopropane, CH), 2.56-2.74 (m, 4H, citric acid, CH2), 
3.29-3.34 (m, 4H, piperazine, CH2- hidden by water peak), 2.72 (d, 
2JH-H= 
15.6 Hz, 1H, H-24/H-28, CH), 2.66 (d, 2JH-H= 14.4 Hz, 1H, H-24/H-28, CH), 
2.62 (d, 2JH-H= 15.6 Hz, 1H, H-24/H-28, CH), 2.57 (d, 
2JH-H= 15.6 Hz, 1H, H-
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24/H-28, CH), 1.30-1.35 (m, 2H, cyclopropane, CH2), 1.12-1.23 (m, 2H, 
cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 177.1 (s, C-22), 175.9 (d, 
4JC-F= 2.3 
Hz, C-6), 172.0 (s, C-25/ C-29), 169.2 (s, C-25/ C-29), 167.7 (s, C-17), 166.6 
(s, C-19), 154.8 (d, JC-F= 201.0 Hz, C-9), 150.7 (s, C-4), 145.6 (d, 
2JC-F= 10.8 
Hz, C-10), 139.7 (s, C-12), 119.3 (d, 3JC-F= 7.2 Hz, C-7), 111.4 (d, 
2JC-F=21.5 
Hz, C-8), 107.2 (d, 3JC-F= 3.2 Hz, C-11), 72.7 (s, C-23), 49.5 (s, C-
13/14/15/16), 49.4 (s, C-13/14/15/16), 43.8 (s, C-20), 43.4 (s, C-13/14/15/16), 
42.8 (s, C-13/14/15/16), 41.0 (s, C-24/ C-28), 40.6 (s, C-24/ C-28), 35.9 (s, C-
3), 7.4 (s, C-1, C-2); 
IR (KBr, cm-1): 3384 (b, OH), 3058 (w, CH), 2919 (w, CH), 2844 (w, CH), 
1720 (m, C=O), 1624 (s, C=O), 1465 (m, CH2), 1386 (m, C-O), 1334 (m, C-O), 
1243 (s, C-F), 1024 (s, C-O); 
m.p. (OC): 179.4-181.2 OC; 
HRMS (ESI): Calc. for C25H27FN4O11 563.1802 [M+H]
+, found  563.1784 (-3.2 
ppm error); 
CID: 563 [M+H]+, 545, 527, 509, 389  and 371 
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4.9 Methyl 7-[4-(2-{[(tert-butoxy)carbonyl]amino}-3-
hydroxypropanoyl) piperazin-1-yl]-1-cyclopropyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (48) 
 
N
O
F
N
N
O NH
O
O
OH
CH3
CH3
CH3
O
O
CH3
48
1 2
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C26H33FN4O7 
532.3 g/mol 
 
To a stirred solution of methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-
1-yl)-1,4-dihydroquinoline-3-carboxylate 42 (0.3 g, 0.869 mmol, 1eq.) and N-
(tert-butoxycarbonyl)-L-Ser-OH 47 (0.18 g, 0.869 mmol, 1eq.) in anhydrous 
acetonitrile: DCM (3:2, 50 mL), was added DIPEA (162 µL, 0.90 mmol) and 
the mixture was stirred for 30 minutes at room temperature. After 30 minutes 
of stirring, HBTU (0.33 g, 0.90 mmol, 1 eq.) was added, and the reaction 
mixture was left to stir for 24 hours at room temperature. 
The solvent was removed in vacuo and the residue was diluted with 
DCM (80 mL) and washed with deionised water (2x 50 mL), 0.05M aqueous 
HCl (2x 50 mL), 0.05M aqueous NaHCO3 (2x 50 mL) and brine (2x 50 mL). 
The organic extract was dried over anhydrous MgSO4 (s), and the solvent 
removed in vacuo. The residue was triturated with toluene giving 48 as a 
cream solid (0.33 g, 0.62 mmol, 72 %). 
Rf= 0.86 (CHCl3: MeOH, 3:1); 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.44 (s, 1H, H-4, CH), 7.76 (d, 
3JH-F= 
13.4 Hz, 1H, H-8, CH), 7.44 (d, 4JH-F= 7.3 Hz, 1H, H-11, CH), 6.88 (d, 
3JH-H= 
8.2 Hz, 1H, NH), 4.53 (sx, 3J20-21= 5.8 Hz,
 3J20-21= 5.8 Hz, 
3J20-23= 8.2 Hz, 1H, 
H-20, CH), 4.44 (s (b), 1H, OH), 3.75-3.83 (m, 2H, piperazine, CH2), 3.73 (s, 
3H, CH3), 3.68-3.72 (m, 2H, piperazine, CH2), 3.63-3.67 (m, 1H, 
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cyclopropane, CH), 3.58 (dd, 3J21-20= 5.8 Hz, 
2J21-21= 11.0 Hz, 1H, H-21), 3.48 
(dd, 3J21-20= 5.8 Hz, 
2J21-21= 11.0 Hz, 1H, H-21, CH), 3.18-3.31 (m, 4H, 
piperazine, CH2), 1.38 (s, 9H, H-26, H-27, H-28, CH3), 1.22-1.27 (m, 2H, 
cyclopropane, CH2), 1.09-1.10 (m, 2H, cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 172.2 (d, 
4JC-F= 2.3 Hz, C-6), 169.7 
(s, C-24), 166.6 (s, C-17), 155.7 (s, C-22), 153.2 (d, 1JC-F= 247.0 Hz, C-9), 
148.9 (s, C-4), 144.1 (d, 2JC-F= 10.7 Hz, C-10), 138.6 (s, C-12), 122.5 (d, 
3JC-F= 
7.6 Hz, C-7), 112.0 (d, 2JC-F= 23 Hz, C-8), 109.4 (s, C-5), 106.9 (d, 
3JC-F= 3.1 
Hz, C-11), 78.4 (s, C-25), 61.8 (s, C-21), 52.3 (s, C-18), 51.4 (s, C-20), 49.9 
(s, C-13/14/15/16), 49.6 (s, C-13/14/15/16), 44.8 (s, C-13/14/15/16), 41.3 (s, 
C-13/14/15/16), 34.8 (s, C-3), 28.1 (s, C-24, C-25, C-26), 7.4 (s, C-1, C-2); 
IR (KBr, cm-1): 3423 (b, OH), 2970 (w, CH), 2945 (w, CH), 2925 (w, CH), 
1695 (s, C=O), 1617 (s, C=O), 1495 (m, CH2), 1474 (m, CH2), 1446 (m, CH2), 
1388 (w, CH3), 1364 (w, CH3), 1343 (w, CH3),  1311 (w, CH3), 1241 (s, C-F), 
1160 (m, C-O), 1082 (m, C-O), 1021 (m, C-O); 
m.p (OC): 270.3-272.7 OC; 
m/z (ESI): 533 ([M+H]+, 100 %); 
HRMS (ESI): Calc. for C26H34FNO7 533.2406 [M+H]
+, found 533.2407 (-0.1 
ppm error).  
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4.10 Methyl 7-{4-[3-(acetyloxy)-2-{[(tert-
butoxy)carbonyl] amino} propanoyl]piperazin-1-yl}-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (50) 
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C28H35FN4O8 
574.6 g/mol 
 
Methyl 7-[4-(2-{[(tert-butoxy)carbonyl]amino}-3-hydroxypropanoyl) 
piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate 48 (0.30 g, 0.57 mmol, 1 eq.) was dissolved in acetic anhydride 
(0.16 mL, 1.70 mmol, 3 eq.). To this was added triethylamine (0.23 mL, 1.70 
mmol, 3 eq.) and DMAP (1.4 mg, 0.01 mol, 0.02 eq.). The reaction mixture 
was allowed to stir at room temperature for 15 minutes.   
The solvent was concentrated in vacuo affording a yellow oily residue 
which was diluted with chloroform (20 mL). The organic phase was washed 
with saturated sodium hydrogen carbonate (NaHCO3, 3x 10 mL) and brine (2x 
10 mL). The organic extract was dried over anhydrous MgSO4 (s), and the 
solvent was removed in vacuo. Crude 50 was purified by column 
chromatography using a solvent system consisting of ethyl acetate: methanol: 
triethylamine (9:1:0.05), giving 50 as a cream solid (0.26 g, 0.45 mmol, 79 %). 
Rf= 0.53 (EtOAc: MeOH: TEA, 9:1:0.05); 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.46 (s, 1H, H-4, CH), 7.79 (d, 
3JH-H= 
13.4 Hz, 1H, H-8, CH), 7.46 (d, 4JH-F= 7.3 Hz, 1H, H-11, CH), 7.33 (d, 
3J21-20= 
8.8 Hz, 1H, NH), 4.74 (sx, 3J20-27= 5.4 Hz, 
3J20-27= 5.4, 
3J20-21= 8.8 Hz, 1H, H-
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20, CH), 4.26 (dd, 3J27-20= 5.4 Hz, 
2J27-27= 11.2 Hz, 1H, H-27, CH), 4.01 (dd, 
3J27-20= 5.4 Hz, 
2J27-27= 11.2 Hz, 1H, H-27, CH), 3.70-3.80 (m, 6H, piperazine, 
CH2, H-18 CH3), 3.63-3.68 (m, 2H, cyclopropane, CH, piperazine, CH2), 
3.17-3.32 (m, 4H, piperazine, CH2), 1.99 (s, 3H, acetyl, CH3), 1.39 (s, 9H, H-
24, H-25, H-26, CH3), 1.21-1.26 (m, 2H, cyclopropane, CH2), 1.07-1.12 (m, 
2H, cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 172.2 (d, 
4JC-F= 2.4 Hz, C-6), 171.0 
(s, C-22), 168.1 (s, C-28), 166.6 (s, C-17), 155.8 (s, C-19), 153.2 (d, JC-F= 
244.8 Hz, C-9), 148.9 (s, C-4), 144.0 (d, 2JC-F= 10.0 Hz, C-10), 138.6 (s, C-
12), 122.6 (d, 3JC-F= 7.5 Hz, C-7), 112.0 (d, 
2JC-F= 23.0 Hz, C-8), 109.4 (s, C-
5), 107.0 (d, 3JC-F= 3.3 Hz, C-11), 78.8 (s, C-23), 63.5 (s, C-27), 51.4 (s, C-18), 
49.6 (s, C-13/14/15/16), 49.5 (s, C-13/14/15/16), 49.0 (s, C-20), 44.6 (s, C-
13/14/15/16), 41.4 (s, C-13/14/15/16), 34.8 (s, C-3), 28.1 (s, C-24, C-25, C-
26), 20.5 (s, C-29), 7.4 (s, C-1, C-2); 
IR (KBr, cm-1): 2974 (w, CH), 2945 (w, CH), 2925 (w, CH), 1728 (s, C=O), 
1621 (s, C=O), 1491 (m, CH2), 1474 (m, CH2), 1442 (m, CH2), 1388 (w, CH3), 
1360 (w, CH3), 1343 (w, CH3), 1311 (w, C-O), 1254 (s, C-F), 1160 (m, C-O), 
1082 (m, C-O), 1021 (m, C-O); 
m. p. (OC): 162.9-167.2 OC; 
m/z (ESI): 575 ([M+H], 100 %); 
HRMS (ESI): Calc. for C28H36FN4O8 575.2512 [M+H]
+, found 575.2527 (0.9 
ppm error). 
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4.11 2-(3-{4-[1-Cyclopropyl-6-fluoro-3-
(methoxycarbonyl)-4-oxo-1,4-dihydroquinoline-7-
yl]piperazin-1-yl}-2-[2-hydroxy-4-methoxy-2-(2-methoxy-
2-oxoethyl)-4-oxobutanamido]-3-oxopropyl) 1,3-dimethyl 
2-hydroxypropane-1,2,3-tricarboxylate (52) 
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C37H45FN4O17 
836.6 g/mol 
 
To a methanolic HCl (4M, 20 mL) at 0-5 OC was added methyl 7-{4-[3-
(acetyloxy)-2-{[(tert-butoxy)carbonyl]amino}propanoyl]piperazin-1-yl}-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 50 (0.25 g, 0.4 
mmol, 1 eq.). The reaction mixture was stirred at room temperature for 1 hour. 
The solvent was removed in vacuo, and anhydrous MeOH (40 mL) and 
triethylamine (0.5 mL) were added, stirring was continued at room 
temperature for 1.5 hours. The reaction was concentrated under reduced 
pressure affording a cream solid. 
The solid residue and 2-hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-
oxobutanoic acid 40 (0.02 g, 0.09 mmol, 2 eq.) were dissolved in anhydrous 
DMF (10 mL), DIPEA (54 µL, 0.31 mmol), HOBt. H2O (0.01 g, 0.09 mmol) and 
EDC.HCl (0.02 g, 0.09 mmol) were added. The reaction mixture was stirred at 
40 OC and small amounts of EDC.HCl (0.02 g, 0.087 mmol) were added every 
3 hours. The reaction mixture was cooled to room temperature and 
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concentrated in vacuo to give an oily residue. The residue was dissolved in 
chloroform (100 mL), washed with saturated NaHCO3 (5x 100 mL) and brine 
(5x 100 mL). The organic extract was dried over anhydrous MgSO4 (s) and 
concentrated in vacuo to give crude 52 which was purified by coulumn 
chromatography on silica gel using a solvent system consisting of chloroform: 
MeOH: TEA (9:1:0.05) to give 52 as a cream solid (0.20 g, 0.2 mmol, 56 %). 
Rf = 0.71 (CHCl3: MeOH: TEA, 3:1:0.05); 
1H NMR (400 MHz, CDCl3) δ (ppm): 8.56 (s, 1H, H-4, CH), 8.06 (d, 
3JH-F= 
12.8 Hz, 1H, H-8, CH), 7.94 (d, 3J21-20= 8.6 Hz, 1H, H-21, NH), 7.23 (d, 
4JH-F= 
7.3 Hz, 1H, H-11, CH), 4.97- 5.02 (m, 1H, H-20, CH), 3.91 (s, 3H, H-18, CH3), 
3.83-3.85 (m, 1H, H-31, CH), 3.77-3.81 (m, 4H, piperazine, CH2), 3.73-3.75 
(m, 1H, H-31, CH), 3.71 (s, 3H, H-26/ H-30/ H-36/ H-39, CH3), 3.70 (s, 3H, H-
26/ H-30/ H-36/ H-39, CH3), 3.67 (s, 3H, H-26/ H-30/ H-36/ H-39, CH3), 3.64 
(s, 3H, H-26/ H-30/ H-36/ H-39, CH3), 3.40-3.45 (m, 1H, cyclopropane, CH), 
3.24-3.29 (m, 4H, piperazine, CH2), 2.77 (d, 
2JH-H= 15.9 Hz, 2H, H-24/ H-28/ 
H-34/ H-37, CH2), 2.94 (d, 
2JH-H= 17.3 Hz, 2H, H-24/ H-28/ H-34/ H-37, CH2), 
2.98 (d, 2JH-H= 15.9 Hz, 2H, H-24/ H-28/ H-34/ H-37, CH2), 2.85 (d, 
2JH-H= 17.3 
Hz, 2H, H-24/ H-28/ H-34/ H-37, CH2), 1.36-1.31 (2H, cyclopropane, CH2), 
1.11-1.16 (2H, cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 173.1 (s, C-22, C-32), 172.7 (d, 
4JC-
F= 2.3 Hz, C-6), 172.0 (s, C-25,C-29, C-35, C-38), 168.1 (s, C-19), 166.6 (s, 
C-17), 146.3 (d, 1JC-F= 247 Hz, C-9), 138.8 (s, C-4), 130.3 (d, 
2JC-F= 10.3 
Hz,C-10), 129.7 (s, C-12), 124.6 (d, 3JC-F= 7.6 Hz, C-7), 114.8 (d, 
2JC-F= 24.4 
Hz, C-8), 110.1 (s, C-5), 104.9 (d, 3JC-F= 3.8 Hz, C-11), 74.3 (s,C-23), 68.2 (s, 
C-33), 63.5 (s, C-31), 52.3 (s, C-26/30/36/39), 52.3 (s, C-26/30/36/39), 52.1 
(s, C-18), 45.5 (s, C-13/14/15/16), 42.9 (s, C-20), 42.6 (s, C-13/14/15/16), 
41.5 (s, C-34, C-37), 38.7 (s, C-24, C-28), 34.2 (s, C-3), 7.4 (s, C-1, C-2); 
IR (KBr, cm-1): 2958 (w, CH), 2929 (w, CH), 2872 (w, CH), 1732 (s, C=O), 
1625 (s, C=O), 1491 (m, CH2), 1437 (m, CH2),1442 (m, CH2), 1372 (s, C-F), 
1262 (w, CH3), 1233 (w, CH3), 1213 (w, CH3); 
m.p. (OC): 211.8-213.3 OC; 
HRMS (ESI): Calc. for C37H46FN4O17 was 837.2837 [M+H]
+, found 837.2849 (-
1.5 ppm error). 
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4.12  3-({1-[4-(3-Carboxy-1-cyclopropyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-7-yl)piperazin-1-yl]-3-hydroxy-1-
oxopropan-2-yl}carbamoyl)-3-hydroxypentanedioic acid 
(39) 
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C26H29FN4O11 
592.5 g/mol 
 
To a stirred suspension of TBAH in methanol (1M, 0.5 mL) and 
deionised water (4.5 mL) was added small portions of 2-(3-{4-[1-cyclopropyl-6-
fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinoline-7-yl]piperazin-1-yl}-2-
[2-hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanamido]-3-
oxopropyl) 1,3-dimethyl 2-hydroxypropane-1,2,3-tricarboxylate 52 (0.15 g, 
0.18 mmol, 1 eq.). The reaction mixture was allowed to stir at room 
temperature for 18 hours. The reaction mixture was neutralised by addition of 
pyruvic acid in deionised water (0.2M, 3 mL). The precipitate formed was 
filtered to give 39 (0.03 g, 0.054 mmol, 30 %). 
Rf= 0.11 (Chloroform: MeOH: Formic acid, 9:1:0.05); 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.67 (s, 1H, H-4, CH), 8.15 (dd, 
3JH-H 
= 4.6 Hz, 3JH-H= 4.2 Hz, 1H, H-21, NH), 7.93 (d, 
3JH-F= 7.5 Hz, 1H, H-8, CH), 
7.58 (d, 4JH-F= 4.2 Hz, 1H, H-11, CH), 4.89 (s b, 1H, OH), 4.84 (m, 1H, H-20, 
CH), 3.63-3.84 (m, 4H, piperazine, CH2, CH, cyclopropane), 3.60 (dd, 
3J31-
20= 3.3 Hz, 
2J31-31= 5.7 Hz, 1H, H-31, CH), 3.46 (dd, 
3J31-20= 3.3 Hz, 
2J31-31= 5.7 
Hz, H-31, CH), 3.22-3.35 (hidden by water peak, CH2, piperazine), 2.70 (dd, 
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2JH-H= 8.8 Hz, 1H, H-24/ H-28, CH), 2.62 (dd, 
2JH-H= 8.1 Hz, 1H, H-24/ H-28, 
CH), 2.59 (dd, 1H, 2JH-H= 8.8 Hz, 1H, H-24/ H-28, CH), 2.55 (dd, 
2JH-H= 8.1, 
1H, H-24/ H-28, CH), 1.29-1.35 (m, 2H, cyclopropane, CH2), 1.14-1.22 (m, 
2H, cyclopropane, CH2); 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 175.9 (s, C-22), 172.1 (d, 
4JC-F= 3.1 
Hz, C-6), 168.9 (s, C-25, C-29), 168.6 (s, C-25, C-29), 166.62(s, C-17), 154.5 
(s, C-19), 152.4 (d, JC-F= 248.0 Hz, C-9), 148.7 (s, C-4), 145.5 (d, 
2JC-F= 10.2 
Hz, C-10), 139.7 (s, C-12), 119.3 (d, 3JC-F= 7.1 Hz, C-7), 110.8 (d, 
2JC-F=22.2 
Hz, C-8), 107.1 (d, 3JC-F= 3.8 Hz, C-11), 72.9 (s, C-23), 61.8 (s, C-31), 50.4 (s, 
C-20), 50.4 (C-13/14/15/16), 49.7 (C-13/14/15/16), 43.3 (C-13/14/15/16), 43.1 
(C-13/14/15/16), 41.8 (s, C-24, C-28), 35.9 (s, C-3), 7.4 (s, C-1, C-2); 
IR (KBr, cm-1): 3412 (b, OH), 3052 (w, CH), 2848 (w, CH), 1732 (s, C=O), 
1650 (s, C=O), 1626 (s, C=O), 1471 (m, CH2), 1454 (m, CH2), 1381 (m, C-O), 
1340 (m, C-O), 1270 (s, C-F), 1021 (m, C-O); 
m.p. (OC): 230.3- 234.7 OC; 
HRMS (ESI +ve): Calc. for C26H30FN4O11 was 593.1890 [M+H]
+, found 
593.1912 (-3.8 ppm error); 
HRMS (ESI -ve): Calc. for C26H28FN4O11 was 591.1744 [M-H]
-, found 591.1763 
(-3.2 ppm error); 
m/z (CID): 593 [M+H]+, 575.2, 557.2, 539.2, 503.2, 419.2 
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5 Appendices 
 
Appendix 1.1H NMR of 1, 5-dimethyl citrate 40 
H-NMR spectrum of 1, 5- dimethyl citric acid.esp
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Appendix 2. 1H NMR of 1, 3, 5-trimethyl citrate 41 
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Appendix 3. 1H NMR of ciprofloxacin methanoate 42 
r1459nmd_PROTON-4.jdf
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
1.931.981.344.064.171.163.251.721.000.98
H- NMR of ciprofloxacin methanoate.esp
1.30 1.25 1.20 1.15 1.10
Chemical Shift (ppm)
H- NMR of ciprofloxacin methanoate.esp
2.25 2.20 2.15 2.10
Chemical Shift (ppm)
H- NMR of ciprofloxacin methanoate.esp
3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1
Chemical Shift (ppm)
H- NMR of ciprofloxacin methanoate.esp
8.5 8.0 7.5
Chemical Shift (ppm)
NN
NH
O
F
O
O
8
4
11
42
1 2
3
18
1/2
1/2
NH
3
19
13
14
15
16
13/14/
15/16
4 8
11
CDCl3
 
Appendix 4. 1H NMR of linker-drug conjugate 44 
H-NMR for N- Boc- gly- cpf methanoate in methanol- aq media.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
2.132.228.901.372.202.333.392.130.910.821.141.01
H-NMR for N- Boc- gly- cpf methanoate in methanol- aq media.esp
1.35 1.30 1.25 1.20 1.15
Chemical Shift (ppm)
H-NMR for N- Boc- gly- cpf methanoate in methanol- aq media.esp
4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2
Chemical Shift (ppm)
H-NMR for N- Boc- gly- cpf methanoate in methanol- aq media.esp
5.525 5.500 5.475
Chemical Shift (ppm)
H-NMR for N- Boc- gly- cpf methanoate in methanol- aq media.esp
8.5 8.0 7.5
Chemical Shift (ppm)
N
O
COOMeF
N
N
O NH
O
O
44
1 2
3
4
7
8
11
13
14
15
16
18
20
21
24
25
26
1/2 1/2
21
20
18
13/14/15/16
3
13/14/
15/16
24/25/26
4
8 11
CDCl3
H2O
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Appendix 5. COSY of linker-drug conjugate 44 
p6352nmd_gDQF_COSY-1.jdf
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
F2 Chemical Shift (ppm)
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
F1
 C
he
m
ic
al
 S
hi
ft 
(p
pm
)
20
NH
 
Appendix 6. 1H NMR of protected siderophore-drug conjuigate 46 
p8374nmd_PROTON-1_jdf.gxd
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
2.152.352.142.144.425.943.375.142.051.420.691.371.17
H-NMR of 1, 5- CA- gly- cpf methanoate.esp
1.30 1.25 1.20 1.15 1.10 1.05
Chemical Shift (ppm)
H-NMR of 1, 5- CA- gly- cpf methanoate.esp
2.85 2.80 2.75 2.70
Chemical Shift (ppm)
H-NMR of 1, 5- CA- gly- cpf methanoate.esp
4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2
Chemical Shift (ppm)
H-NMR of 1, 5- CA- gly- cpf methanoate.esp
8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5
Chemical Shift (ppm)
1/2 1/2
4
8NH
11
N
O
COOMeF
N
N
NH
O
O
MeOOC
MeOOC
OH
46
1 2
3
4
8
11
13
14
15
16
18
20
21
24
26
28
30
20
18
26, 30
13/14/15/16
13/14/15/16, 
3
24/29 24/29
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Appendix 7. 1H NMR of linker-drug conjugate 48 
N-Boc- L- ser- cpf methanoate in DMSO-d6 edited triplet resonance.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
12.693.561.268.730.971.340.870.931.151.00
N-Boc- L- ser- cpf methanoate in DMSO-d6 edited triplet resonance.esp
8.0 7.5 7.0
Chemical Shift (ppm)
N-Boc- L- ser- cpf methanoate in DMSO-d6 edited triplet resonance.esp
4.60 4.55 4.50 4.45 4.40 4.35
Chemical Shift (ppm)
N-Boc- L- ser- cpf methanoate in DMSO-d6 edited triplet resonance.esp
3.80 3.75 3.70 3.65 3.60 3.55 3.50 3.45 3.40 3.35 3.30 3.25 3.20
Chemical Shift (ppm)
N
O
COOMeF
N
N
O NH
O
O
OH
1 2
3
4
8
10
11
13
14
15
16
17 18
20
21
22
23
26
27
28
1/2
1/2
4
8
11
NH
OH
20
13/14/15/16
3
21 21
13/14/15/16
18
26/27/28
DMSO-d6
H2O
1.esp
1.25 1.20 1.15 1.10
Chemical Shift (ppm)
48
 
Appendix 8. COSY of linker-drug conjugate 48 
p6287nmd_gDQF_COSY-1.jdf
7 6 5 4 3 2 1 0
F2 Chemical Shift (ppm)
1
2
3
4
5
6
7
F
1
 C
h
e
m
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l 
S
h
if
t 
(p
p
m
)
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Appendix 9. 1H NMR of linker-drug conjugate 50 
H-NMR for N- Boc- acetyl- L- ser- ciprofloxacin methanoate.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1.721.808.582.803.561.725.561.321.061.120.871.001.040.97
1.esp
1.2 1.1
Chemical Shift (ppm)
1.esp
3.80 3.75 3.70 3.65 3.60 3.55 3.50 3.45 3.40 3.35 3.30 3.25 3.20 3.15
Chemical Shift (ppm)1.esp
4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0
Chemical Shift (ppm)1.esp
8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4
Chemical Shift (ppm)
N
O
F
N
N
O NH
O
O
O
O
O
O
1 2
3
4
8
11
13
14
15
16
18
20
21
24
25
26
27
29
50
1/2 1/2
4
8
11 NH
27 2720
3, 13/14/15/16 13/14/15/16
18, 
13/14/
15/16
29
24,25,26
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